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Abstract
Cancer rates are set to increase at an alarming rate, from 10 million new cases globally in 2000 to
15 million in 2020. Regarding the pharmacological treatment of cancer, we currently are in the
interphase of two treatment eras. The so-called pregenomic therapy which names the traditional
cancer drugs, mainly cytotoxic drug types, and post-genomic era-type drugs referring to rationally-
based designed. Although there are successful examples of this newer drug discovery approach,
most target-specific agents only provide small gains in symptom control and/or survival, whereas
others have consistently failed in the clinical testing. There is however, a characteristic shared by
these agents: -their high cost-. This is expected as drug discovery and development is generally
carried out within the commercial rather than the academic realm. Given the extraordinarily high
therapeutic drug discovery-associated costs and risks, it is highly unlikely that any single public-
sector research group will see a novel chemical "probe" become a "drug". An alternative drug
development strategy is the exploitation of established drugs that have already been approved for
treatment of non-cancerous diseases and whose cancer target has already been discovered. This
strategy is also denominated drug repositioning, drug repurposing, or indication switch. Although
traditionally development of these drugs was unlikely to be pursued by Big Pharma due to their
limited commercial value, biopharmaceutical companies attempting to increase productivity at
present are pursuing drug repositioning. More and more companies are scanning the existing
pharmacopoeia for repositioning candidates, and the number of repositioning success stories is
increasing. Here we provide noteworthy examples of known drugs whose potential anticancer
activities have been highlighted, to encourage further research on these known drugs as a means
to foster their translation into clinical trials utilizing the more limited public-sector resources. If
these drug types eventually result in being effective, it follows that they could be much more
affordable for patients with cancer; therefore, their contribution in terms of reducing cancer
mortality at the global level would be greater.
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Background
At present, cancer remains a significant health problem
worldwide. According to International Agency for
Research on Cancer-World Health Organization (IARC-
WHO) estimates, cancer rates are set to increase at an
alarming rate, from 10 million new cases globally in 2000
to 15 million in 2020 [1]. Cancer statistics from the U.S.
show a total of 1,368,030 new cancer cases and 563,700
deaths expected; paradoxically, there has been a decrease
or stabilization in mortality rates from cancer, particularly
in major cancers such as lung, colorectal, prostate, and
breast. A recent estimate of trends in 5- and 10-year rela-
tive survival of cancer patients in the U.S. in 1998–2003
from the 1973–2003 Surveillance, Epidemiology, and
End Results Program data base indicated significant
improvements in 5- and 10-year relative survival for 14 of
24 assessed common forms of cancer, such as prostate,
breast, and colorectal cancer. Improvements in long-term
survival were strongest for prostate cancer, non-Hodgkin
lymphoma, and kidney cancer. In general, these improve-
ments are likely the result of progress in early detection,
treatment, or both, depending on tumor type [2].
With regard to cancer treatment with drugs, we are cur-
rently in the interphase of two treatment eras. So-called
pregenomic therapy names the traditional cancer drugs,
mainly cytotoxic drug types. This tagging stems from the
fact that in general terms, pregenomic cancer drugs were
empirically developed based mainly on their capacity to
inhibit cancer growth in experimental systems regardless
of their nature and potential mechanism of action. Con-
trariwise, post-genomic era-type drugs refer to rationally
based designed drugs in which the startpoint comprises,
first, target identification, second, demonstrating that can-
didate drugs inhibit this target, and third, proving that
cancer growth is affected as a consequence of target inhi-
bition.
Whereas the scientific basis for development of these drug
classes is strong, our current level of knowledge on the
molecular basis of cancer remains a limitation for this
design type. To date, successful examples of this newer
drug discovery approach are noteworthy, and just to men-
tion a few we site dramatic results with the use of bcr-abl-
and c-kit-targeting agents on chronic granulocytic leuke-
mia and gastrointestinal stromal tumors, the impressive
results of Epidermal growth factor receptor (EGFR) inhib-
itors in a small subset of non-small-cell lung cancer, and
the efficacy of targeting HER2 by a monoclonal antibody
in approximately 30% of patients with breast cancer
whose tumors overexpress this oncoprotein. There are
many other examples of these drug classes that are already
commercially available for the treatment of cancer; how-
ever, these pharmaceuticals only provide, albeit signifi-
cantly, small gains in symptom control and/or survival,
whereas others have consistently failed in the clinical test-
ing stage. This picture of the heterogenous results of so-
called targeted therapies with respect to their clinical effi-
cacy underscore that while these efforts must continue,
parallel efforts are strongly required in cancer biology
research for improved prediction of the target to be
approached that offer the highest treatment benefit prob-
ability. As previously mentioned, these agents are solely
effective in tumor types dependent on the pathways being
inhibited. It is readily apparent that the majority of solid
tumors are the result of numerous genetic and epigenetic
alterations; hence, inhibiting a single cellular pathway
may not result in significant therapeutic activity. Design of
agents that target a number of pathways will possibly
increase the therapeutic effect, but could also increase the
risk of treatment-related toxicities [3,4].
While it is obvious that the vast majority of knowledge on
cancer biology has been generated by investigators from
public and non-profit organizations, drug discovery and
development is generally carried out within the commer-
cial rather than the academic realm, given the extraordi-
narily high therapeutic drug discovery-associated costs
and risks. Thus, it is exceedingly unlikely that any single
public-sector research group will successfully see a novel
chemical "probe" become a "drug".
Classical drug discovery involves target discovery and val-
idation, lead identification by high-throughput screening,
and lead optimization by medicinal chemistry. Pre-clini-
cal follow-up evaluation includes analysis in animal mod-
els of compound efficacy and pharmacology
(Administration, distribution, metabolism, elimination
[ADME]) and toxicology, specificity, and drug interaction
studies. The high-risk/high-reward aspect of drug discov-
ery comprises a greater issue in the commercial realm in
terms of new-compound approval and marketability.
Therefore, oncological products are subject to the laws of
marketing; hence, the majority of the newer cancer prod-
ucts are simply cost-prohibitive to the vast majority of
patients worldwide, which has been widely approached
and reviewed [5-7]. This important issue has led research-
ers at non-profit academic organizations to reflect upon
alternatives for cancer drug development [8,9].
An alternative drug development strategy is the exploita-
tion of established drugs that have already been approved
for treatment of non-cancerous diseases and whose cancer
target has already been discovered. This strategy is also
denominated drug repositioning, drug repurposing, or indica-
tion switch. Although traditionally development of these
drugs was unlikely to be pursued by Big Pharma due to
their limited commercial value, biopharmaceutical com-
panies attempting to increase productivity at present are
pursuing drug repositioning. More and more companies areMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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scanning the existing pharmacopoeia for repositioning
candidates, and the number of repositioning success sto-
ries is increasing [10]. The best known example is that of
sildenafil (Viagra; Pfizer), which was initially developed
as an anti-angina medication but possessed the side effect
of producing prolonged penile erections in human volun-
teers [11].
The major advantage of this approach is that the pharma-
cokinetic, pharmacodynamic, and toxicity profiles of
drugs are in general well known; thus, their rapid transla-
tion into clinical phase II and III studies is feasible. On the
other hand, from the commercial point of view and
despite that repositioning is observed as a not-very-reward-
ing adventure, pharmaceutical companies can exploit a
number of strategies to add value to this drug develop-
ment type, such as inventing novel formulations, dosage
forms, drug combinations, or geographic strategies that
create new barriers to entry. In addition, intellectual prop-
erty-type  composition-of-matter  and  use  patents can be
granted, as well as marketing exclusivity for different time
periods for Federal Drug Administration (FDA) approval
of new indications in a pediatric population, for a known
compound for a new indication, a new chemical entity, or
in an orphan population [10].
The process of repositioning and in particular in the cancer
therapeutic field is not yet systematized. As shown in this
review, clues for cancer activities of the majority of non-
cancer drugs presented arose from serendipity and novel
insights into the molecular pathology of cancer, for exam-
ple, the realization that AMP-activated protein kinase
(AMPK), the target of metformin is also a cancer target,
and so on. Off-target toxicity also serves as a way to dis-
cover antitumor effects of known drugs, for instance, the
effects on the DNA methylation-autoimmune disease of
drugs such as procainamide and hydralazine. Although
this approach may be efficient with effective drugs, it is
biased and limited to a single drug type.
Recently, O'Connor and Roth [9] proposed an approach
more likely to be successful in achieving the ultimate goal
of providing new drugs, one in which already available
medications – the majority of which are off-patent – are
simultaneously screened employing several in vitro and in
vivo model systems. This approach utilizes existing medi-
cations that are subsequently used as probes for pre-clini-
cal molecular target- or phenotype-based drug discovery
efforts. In contrast, the proposed approach blindly screens
existing compounds against a multitude of targets, and
therefore identifies either possible therapeutic benefits or
side effects in a non-biased fashion.
The objective of this review was to provide noteworthy
examples – but not a comprehensive review on each of
these – of known drugs whose potential anticancer activi-
ties have been highlighted, to encourage further research
on these known drugs as a means to foster their transla-
tion into clinical trials utilizing the more limited public-
sector resources [Table 1]. If these drug types eventually
result in being effective, it follows that they could be much
more affordable for patients with cancer; therefore, their
contribution in terms of reducing cancer mortality at the
global level would be greater.
Cardiovascular agents
Calcium channel antagonists (CCA) as antihypertensives and 
antiarrhythmics
The antihypertensive and antianginal effectiveness of CCA
have been documented for more than 30 years. Since that
time, these agents have enjoyed increasingly widespread
use in the management of high blood pressure, angina
pectoris, and certain cardiac arrhythmias. Calcium ions
(Ca2+) are the most important cellular messengers in biol-
ogy [12]. Ca2+ entry into the mammalian cell cytosol ini-
tiates such responses as excitation and contraction. Ca2+
entering human heart cells also regulates pacemaking and
atrioventricular conduction, and may influence cell
growth and differentiation. Ca2+ enters the cell through
plasma membrane channels that are members of a large
family of ion channels. The most important Ca2+ channels
in the cardiovascular system are the voltage-gated chan-
nels, which are opened by changes in membrane poten-
tial. There are at least six types of voltage-gated Ca2+
channels, including L-, N-, P-, Q-, R-, and T-type channels.
N-, P-, Q-, and R-type channels are located in neurons,
while L- and T-types are localized in the cardiovascular
system [13]. L-type Ca2+ channels are the most important
plasma membrane Ca2+ channels in heart and vascular
smooth muscle and bind Ca2+ channel blockers currently
used in clinical practice, including dihydropyridines (e.g.,
nifedipine), phenylalkylamines (e.g., verapamil), and
benzothiazepines (e.g., diltiazem).
CCA vary in chemical structure and clinical effects. All
commercially available agents target the L-type channel.
Diltiazem and verapamil are non-selective agents, and
both at equivalent concentrations cause vasodilation,
depress cardiac contractility, and inhibit atrioventricular
conduction, this in contrast to predominant vasodilation
exerted by dihydropyridines (nifedipine and
amlodipine). The therapeutic uses of these agents rely on
their chemical structure and cardiovascular profile.
Diltiazem and verapamil are effective in angina and high
blood pressure, as well as against certain cardiac arrhyth-
mias due to their ability to inhibit atrioventricular con-
duction [14,15].Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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Calcium channel antagonists as anticancer agents
Calcium is recognized as an important regulator of many
essential cellular functions, and in the majority of prolif-
erating cells calcium acts as a general mitogen to stimulate
growth. Other mitogenic effect-associated second messen-
gers include generated phospholipids and diacylglycerol.
It has been shown that in the presence of diacylglycerol,
protein kinase C is activated by a rise in cytosolic-free cal-
cium [16,17]. Once activated, protein kinase C isoen-
zymes catalyze the phosphorylation of a number of
Table 1: Summary of noncancer drugs, their primary indication, noncancer and cancer targets
AGENT PRIMARY INDICATION ON-TARGET Primary effects ON-TARGET Antitumor 
effects
OFF-TARGET Antitumor 
effects
CCA
Verapamil Diltiazem Anti-arrhytmic L-type Ca2+ channels L-type Ca2+channels Voltage-gated K+ channels 
MDR proteins
Inotropics
Digitalis Heart failure Na(+)/K(+)-ATPase Na(+)/K(+)-ATPase Death receptors Glycolysis
RAS
Losartan Hypertension ACE, AT1R AT1R
Captopril Heart failure
Antianginal
Nitroglycerin CHD GMP cGMP
Alpha1-adrenoceptor antagonists
Terazosin Hypertension A1R A1R EGFR
Alfuzosin BPH
Prazosin
Vasodilator
Hydralazine Hypertension Unknown DNA methylation
Antiarrhytmic
Procainamide Arrhytmias Na+ channels DNMT1
Local anesthetic
Procaine Local anesthesia Na+ channels DNA methylation
Antiepileptic
Valproic acid Epilepsia GABA ergic Blocking NMDA Na+ channels Class I-II HDACs PPARγ
Antidiabetics
Glitazones Diabetes mellitus PPARγ PPARγ
Metformin Diabetes mellitus AMPK AMPK
Antiobesity
Orlistat Obesity Fatty-Acid Synthase Fatty-Acid Synthase
Cholesterol lowering agents
Statins Cholesterolemia HMGC HMGC
Antimalarial
Chloroquine Malaria Lysosomas Lysosomas Autophagia
Abortive
Mifepristone Abortion Progesterone receptor Progesterone receptor MDR/MPR
Italic fonts indicate that the targets are shared by the pathological conditions (on-target effects).
Underlined fonts indicate that the antitumor effect is explained by different targets (off-target effects).
This table indicates that some "benign" conditions share molecular alterations with malignant diseases (one target-several indications).
CCA: calcium channel antagonists; RAS: renine-angiotensin-system; CHD: coronary heart disease; BPH: benign prostatic hyperplasia.Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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cellular proteins necessary for proliferation [16-18]. In
addition, transient rises in cytosolic calcium have shown
to initiate activation of the calcium receptor calmodulin,
which may also play an important role in the regulation
of proliferation [16]. Tumors are generally recognized as
possessing unusually high calcium levels. It has been sug-
gested that the high calcium level is due to either excessive
influx of extracellular calcium or the ability of neoplastic
mitochondria to retain higher calcium concentrations
[19]. It is plausible that high intracellular calcium levels
yield increased calcium second-messenger system activa-
tion [19]. CCA have demonstrated to induce apoptosis
and decrease cellular proliferation in many cancer cell
lines in vitro and in vivo by a yet undefined mechanism
that may or not depend on blocking any ionic channels
including L-type channels, because in many studied sys-
tems cells do not express voltage-operated calcium chan-
nels, nor has inhibition of calcium-dependent, secondary-
messenger system inhibition been demonstrated consist-
ently [20-27]. Possible mechanisms of growth inhibition
by CCA include interference with the action of protein
kinase C, calmodulin, and phosphodiesterase, or the c-ras
oncogene guanosine triphosphate-binding protein [28].
CCA also increase cytotoxicity when added to chemother-
apy, an effect attributed to blocking the multidrug resist-
ance protein P-glycoprotein, which acts as an adenosine
triphosphate-dependent drug efflux pump, reducing
intracellular chemotherapeutic drug accumulation [29].
The first clinical testing of CCA against cancer exploited
their anti-mdr action for increasing sensitivity to cytotoxic
anticancer drugs. In a prospective study in 99 patients
with anthracycline-resistant metastatic breast carcinoma
randomized to vindesine-5FU with or without verapamil,
treatment was well tolerated and no verapamil-attributed
side effects were detected. Response and survival were sta-
tistically superior in patients receiving verapamil [30].
Increased responses and survival were also observed in a
trial performed in 72 patients with non-small-cell lung
cancer randomized to vindesine-ifosfamide-mesna plus
minus verapamil [31]. However, a phase III randomized
study of vincristine, doxorubicin, and dexametasone
(VAD) against the same regimen plus oral verapamil in
patients with refractory myeloma reported in 1995 failed
to show a survival advantage. Response rates were similar,
with an overall response rate of 41% for the VAD-alone
arm and 36% for the VAD/v arm. Overall survival of
patients was also similar, with median survival of 10
months for the VAD arm and 13 months for the VAD/v
arm [32]. The results of this trial discouraged clinical
investigation of CCA in further phase III trials. However,
an important question remaining comprises whether this
apparent lack of efficacy is due to that the trial was under-
powered. For the sake of placing this trial into perspective,
the approval of bortezomib for refractory multiple mye-
loma was based on a comparison against high-dose dex-
ametasone in 669 patients [33].
Current research efforts concerning CCA in cancer are
focused on meningioma. Diltiazem, verapamil, and
nifedipine have shown to induce growth inhibition in
meningioma cell cultures, as well as in a mouse xenograft
model [34-38]. In addition, diltiazem and verapamil
added to HU or RU486 increase meningioma growth
inhibition in vitro by inducing apoptosis and G1 cell-cycle
arrest and in vivo by affecting microvascular density [39].
On this basis, a clinical trial program of verapamil alone
or with hydroxyurea as treatment for recurrent or refrac-
tory meningioma is ongoing [40].
Digitalics as inotropics for heart failure
Positive inotropic agents are employed to improve the
impaired cardiac contractility that characterizes chronic
heart failure, and digitalics are the traditional drugs
administered for this purpose. The most commonly used
preparation of digitalis is digoxin, obtained from the
leaves of Digitalis lanata, a common flowering plant
known as foxglove. Digitalis inhibits active sodium and
potassium transport across cell membranes by specific-
site binding to the extracytoplasmic surface of the
sodium- and potassium-activated adenosine triphos-
phatase (NaK ATPase) alpha subunit pump; this binding
is a reversible process. The net result is an increase in intra-
cellular sodium and calcium concentrations and a
decrease in intracellular potassium concentration. Digi-
talis increases phase 4 of the action potential in the major-
ity of myocardial tissue, leading to a reduction of
conduction velocity with increased automaticity and
ectopic activity. Improved inotropy is due to increased
cytosolic calcium-ion concentration during systole. Digi-
talis additionally possesses a negative chronotropic action
that is partly a vagal effect and partly a direct effect on the
sinoatrial node [41-43].
The therapeutic daily dose of digoxin ranges from 0.005
mg/kg in premature infants to as much as 0.75 mg in
adults. Digoxin tablet absorption is 70–80%, while its
bioavailability is 95%. The kidney excretes 60–80% of the
digoxin dose unchanged. Onset of action via oral admin-
istration occurs in 30–120 minutes; onset of action with
intravenous (i.v.) administration occurs in 5–30 minutes.
Peak effect with PO dosing is 2–6 hours, and that with i.v.
dosing is 5–30 hours. Only 1% of the total amount of dig-
oxin in the body is in the serum; of this amount, approx-
imately 25% is protein bound. Volume of distribution is
6–10 L/kg in adults, 10 L/kg in neonates, and as much as
16 L/kg in infants and toddlers. At therapeutic levels,
elimination half-life is 36 hours with renal excretion. In
acute digoxin intoxication in toddlers and children, aver-
age plasma half-life is 11 hours. With acute intoxication,Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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time zero-extrapolated plasma concentrations are lower
in toddlers than in infants and older children due to their
increased distribution and clearance volumes [44,45].
The lethal dose of digoxin is considered as 20–50 times
the maintenance dose taken at once. In healthy adults, a
dose of < 5 mg seldom causes severe toxicity, but a dose of
> 10 mg is nearly always fatal. In pediatric population,
ingestion of > 4 mg or 0.3 mg/kg portends serious toxicity.
Although digitalis-intoxication incidence and severity is
decreasing, surveillance of this important complication of
therapy is essential. Digoxin-interacting drugs are numer-
ous and include amiodarone, propafenone, quinidine,
verapamil, nifedipine, diltiazem, levothyroxine,
cyclosporine, flecainide, disopyramide, omeprazole, tet-
racycline, and erythromycin. These agents affect digoxin
clearance or absorption, thus necessitating digoxin-dose
alteration in patients taking these medications. Further-
more, patients with renal insufficiency may require a
downward-adjusted digoxin dose to avoid digitalis intox-
ication [46,47].
Numerous studies confirm that digoxin does not prolong
survival in patients with systolic heart failure, but the drug
is associated with reduced hospital admissions, improved
functional class, reduced symptoms of heart failure, and
improved quality of life. Digoxin is also an effective agent
against atrial tachyarrhythmias at rest in patients with left
ventricular dysfunction, but exhibits limited efficacy in
controlling ventricular atrial-arrhythmia rate during exer-
tion [48,49].
Digitalics as anticancer agents
Accumulating pre-clinical and clinical data suggests that
digitalic drugs might be used in cancer therapy. Early
observations reported that patients with breast cancer
receiving digitalis had tumor cells with more benign char-
acteristics than tumor cells in patients not receiving this
cardiac glycoside, as well as an apparent lower recurrence
rate [50].
Recent reports have shown that ouabain and related digi-
talics can inhibit growth and induce apoptosis in human
cancer cells in culture and xenografted in immunodefi-
cient mice at concentrations commonly found in the
plasma of cardiac patients treated with this drug [51].
These effects are highly selective for human cells and
depend on Na(+)/K(+)-ATPase inhibition, because stud-
ies on [3H] ouabain binding demonstrate that, in com-
parison with human cell lines, no significant binding of
the drug is observed in mouse- and Chinese hamster-
derived cells, which are resistant to the antiproliferative
effects of these drugs. Thus, Na+/K+ ATPase from cells of
the resistant species is inhibited at much higher concen-
trations of ouabain and digitoxin in comparison with the
human cell enzyme, and good correlation is observed
between these concentrations and those reported for
enzyme inhibition from isolated heart muscles of the
same species [52].
The physiological effects of digitalis on blood pressure
and cardiac activity are consistent with an Na(+)-concen-
tration intracellular increase due to Na(+)/K(+)-ATPase
inhibition, which leads to increased intracellular Ca(2+)
concentration ([Ca(2+)](i) via a backward-running
Na(+)/Ca(2+) exchanger. Contrariwise, antiproliferative
effects could depend on signalling pathways induced by
cardiac glycoside interaction with the Na(+) pump via
intramembrane and cytosolic protein-protein interactions
[53].
Signalling is initiated by interacting with neighboring
membrane proteins and organized cytosolic cascades of
signaling molecules. Diverse mechanisms reported as spe-
cifically involved in cardiac glycoside-mediated malignant
cell-proliferation control has been compiled, are reviewed
in [54-58], and include activation of ERK1/2 activation,
increased cell cycle inhibitor p21Cip1 expression, and
consequent cell cycle-progression inhibition (through
decreased cyclin protein expression), inhibition of tran-
scription factors such as Nuclear factor-kappaB (NF-κB)
and Activator protein-1 (AP-1), inhibition of Akt and
related critical phosphoinositide-3 kinase (PI3K)-path-
way components, sustained Reactive oxygen species
(ROS) production with consequent mitochondrial injury
and reduction in expression of anti-apoptotic proteins
such as Bcl-xL and Bcl-2. In addition to their antiprolifer-
ative effects, experimental evidence indicates that cardiac
glycosides are effective apoptotic inducers through an
increase in Fas and Tumor necrosis factor receptor 1
(TNFR1) expression and by Apo2L/TNF-related apopto-
sis-inducing ligand (TRAIL) in non-small-cell lung cancer
[59-61]. Induction of autophagia has also been reported.
Human PANC-1 pancreatic cancer cell-treated cardiac gly-
cosides exhibit clear hallmarks of autophagy, including
damaged mitochondria-associated autophagosome body
formation and light chain-1 protein expression, an early
indicator of autophagosome formation [62].
Interestingly, there is evidence that cardiac glycosides have
a selective growth inhibitory effect on malignant over nor-
mal cells, which in part could be related with glycolysis
inhibition [63,64]. Moreover, these display selective radi-
osensitizing properties in malignant cells [65-67]. This
selectivity has yet to be studied, but may depend on alpha-
subunit 1 and 3 normal and malignant tissue expression
pattern. Increased expression of α3 over α1 has been
observed in primary colon cancer tumors and cell lines,
[68]. To the contrary, α1 subunit overexpression has been
regarded as the therapeutic target in glioblastoma andMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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lung carcinomas [69-71]. Further studies on the expres-
sion pattern of these subunits may aid in understanding
the antitumor effects of digitalis and may be potentially
utilized as predictive response factors.
Taken together, all this experimental evidence supports
the clinical testing of cardiac glycosides despite their nar-
row therapeutic index. Currently, a phase II study of sec-
ond-line erlotinib plus digoxin in patients with non-
small-cell lung cancer is ongoing.
Renin-angiotensin system (RAS) antagonists as cardiovascular agents
Angiotensin II (AngII), the biologically active peptide of
the renin-angiotensin system (RAS), is a major blood
pressure and cardiovascular homeostasis regulator and is
also recognized as a potent mitogen. AngII is an octapep-
tide produced by cleavage of the inactive decapeptide
Angiotensin I (AngI) by Angiotensin I-converting enzyme
(ACE), a zinc metalloprotease found in the circulation or
bound to the cell membrane. AngI itself is produced by
enzymatic cleavage of the angiotensinogen precursor by
renin. In addition to plasma AngII production, a local RAS
has shown to be functional in several organs, leading to
production of AngII, which might have a paracrine or
autocrine function. AngII mediates its biological effects
through binding to two subtypes of receptors, AT1R and -
2R, which belong to the G-protein-coupled receptor super-
family, but that have different tissue distribution and
intracellular signaling pathways [72,73]. The majority of
AngII's physiological effects have been attributed to stim-
ulation of the AT1R – further subdivided into AT1aR and -
2bR in rodents – whereas AT2R often functions as a coun-
ter-regulatory receptor. In addition to its effects on blood
pressure, AngII has shown to play a role in various patho-
logical situations involving tissue remodeling, such as
wound healing, and cardiac hypertrophy and develop-
ment [74,75].
Angiotensin-converting enzyme inhibitors (ACE-I) were
introduced approximately 20 years ago as antihyperten-
sive agents and have since become one of the most suc-
cessful therapeutic approaches for high blood pressure,
congestive heart failure, post-Myocardial infarction, and
diabetic nephropathy. This wide range of indications is a
consequence of the fact that ACE-I are thought to possess
organ-protective features that extend beyond their ability
to control BP. Approximately 10 years ago, the first orally
active, selective antagonists of the Ang II AT1-receptor, the
sartans, were introduced into clinical practice. These drugs
differ from ACE-I in that they selectively block one of the
Ang II AT receptors, the AT1-receptor, which is responsible
for known Ang II cardiovascular actions. They do not
interfere directly with kinin breakdown and leave other
AT receptors, notably the AT2-receptor, unopposed
[76,77].
These drugs are in general well tolerated. A number of
agents of each class are currently clinically available.
Among ACE-I, at least nine agents are commonly used,
including benazepril, captopril, enalapril, fosinopril, lisinopril,
moexipril, quinapril, ramipril, and trandolapril. The majority
of these agents are taken orally once a day. A dry, irritating
cough is the most common side effect, but angioedema is
the most serious; if it affects the oropharynx, can be fatal.
Angioedema is most frequently found among blacks and
smokers. ACE inhibitors may increase serum K and creat-
inine levels, especially in patients with chronic renal fail-
ure and those taking K-sparing diuretics, K supplements,
or non-steroidal anti-inflammatory drugs. ACE inhibitors
are the least likely of the antihypertensives to cause erec-
tile dysfunction, and are contraindicated during preg-
nancy. In patients with a renal disorder, serum creatinine
and K levels are monitored at least q 3 months. Patients
who have stage 3 nephropathy (estimated GFR of < 60
mL/min to > 30 mL/min) and are administered ACE
inhibitors can usually tolerate up to a 30–35% increase in
serum creatinine above baseline. ACE inhibitors can cause
acute renal failure in patients who are hypovolemic or
who have severe heart failure, severe bilateral renal artery
stenosis, or severe stenosis in the artery to a solitary kid-
ney. Similarly, there are a number of orally available angi-
otensin II receptor blockers such as candesartan, eprosartan,
irbesartan, losartan, olmesartan, telmisartan, and valsartan.
These agents may be safely begun in persons < 60 years of
age with initial serum creatinine of ≤ 3 mg/dL. Adverse-
event incidence is low; angioedema occurs, but much less
frequently than with ACE inhibitors. Precautions for angi-
otensin II receptor blocker use in patients with renovascu-
lar hypertension, hypovolemia, and severe heart failure
are the same as those for ACE inhibitors. Angiotensin II
receptor blockers are contraindicated during pregnancy
[78-83].
Renin-angiotensin system (RAS) antagonists as anticancer agents
Angiotensin II (AngII), the biologically active peptide of
the renin-angiotensin system (RAS), is also recognized as
a potent mitogen that participates in various pathological
situations involving tissue remodeling. The role of AngII
in cell proliferation and migration, as well as in several
experimental angiogenesis models, suggests that the RAS
system may be involved in tumorigenesis. Recent studies
have revealed local expression of several RAS components
in various cancer cells and tissues, including brain, lung,
and pancreatic cancers, as well as breast, prostate, skin,
and cervix carcinomas [84].
The idea that ACE inhibitors might play a protective role
in cancer was suggested by observations of reduced inci-
dence of breast and lung cancer in patients undergoing
long-term treatment with the captopril, lisinopril, or enal-
april [85]. Further suggestions obtained from the findingMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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of lower cancer risk exhibited by individuals homozygous
for I or A alleles at the ACE gene, which is associated with
lower ACE levels [86,87], as well as lower risk of tumor
progression in patients with gastric cancer carrying the
polymorphism [88]. In experimental systems, the antitu-
mor effects of diverse ACE inhibitors show that these
inhibit cell proliferation and possess antiangiogenic,
antimetastatic and anti-inflammatory effects [89-93].
These antitumor properties are also demonstrated by a
number of sartans, selective Ang II AT1-receptor antago-
nists [94-101], further reinforcing that blockade of AT1R
could be an effective anticancer strategy, not only because
these drugs target cancer cells, but also endothelial cells at
the tumor and stroma.
Major intracellular pathways that might be involved in
potential AT1R effects in cancer cell proliferation, angio-
genesis and inflammation are those whose participation
in cancer is well known. AT1R is able to transactivate EGFR
in cancer cell lines, which leads to ERK, STAT3, and PKC
activation [102-105]. The known AT1R proangiogenic
effect mainly results from VEGF, angiopoietin-2, and
VEGFR2 up-regulation via EGFR transactivation [106] in
tumor cells, as well as VEFG up-regulation in fibroblasts,
the major stromal cellular components involved in
tumor-related angiogenesis by activating NFkB, AP-1, and
PKC activation. further, the AT1R subtype also displays
anti-apoptotic effects in microvascular endothelial cells
by up-regulating survivin and suppressing caspase-3 activ-
ity via phosphoinositide-3 kinase PI-3K-Akt-pathway acti-
vation [106,107]. RAS activation through AT1R up-
regulates several inflammatory cytokines and chemokines
[e.g., interleukins (IL)-6/12 and -8, and monocyte chem-
oattractant protein-1 (MCP-1)] via signaling pathways
involving nuclear factor kappa B (NFkB), activator pro-
tein-1 (AP-1) and ROS [108,109]. Some angiotensin type
1 receptor blockers, such as telmisartan, candesartan, irbe-
sartan, and losartan, are peroxisome proliferator-activated
receptor-gamma pathway agonists; hence, this pathway
may also explain some antitumor effects of these agents
[110].
Thus, RAS antagonists – either ACE inhibitors or AT1R
blockers already in use as antihypertensive drugs with
mild side effects – should be considered for clinical devel-
opment as anticancer treatment. To date, a pilot study in
patients with hormone refractory prostate cancer has
shown prostate specific antigen (PSA) changes in eight
(34.8%) of 23 patients treated with candesartan 8 mg
once daily. Six males with a PSA decline of > 50% demon-
strated performance status improvement, and mean time
to PSA progression (TTPP) in responders was 8.3 months
(range, 1–24 months). Only one patient showed low
blood pressure during treatment [111]. These results fur-
ther support the clinical development of these classes of
anticancer agents.
Nitroglycerin for coronary heart disease
Coronary artery disease is a leading cause of morbidity
and mortality in many developed and developing coun-
tries. Management of this condition relies on risk factor
modification and the use of drugs such as antiplatelets,
beta blockers, nitrates, calcium channel blockers, and
revascularization if symptoms persist despite medical
therapy and ACE inhibitors and statins [112,113].
Nitrates improve the balance between myocardial oxygen
supply and demand primarily by decreasing oxygen
demand, and decreases myocardial oxygen demand by
reducing preload via peripheral vein dilation. Nitrates
also improve myocardial oxygen supply by dilating epi-
cardial coronary arteries and collateral vessels, leaving
resistance vessels alone [114]. Nitroglycerin (glyceryl trin-
itrate [GTN]), a potent smooth-muscle relaxant and
vasodilator originally manufactured by Alfred Nobel, has
been employed to treat angina and heart failure for > 130
years. Its main sites of action are in the peripheral vascular
tree, especially in the venous or capacitance system, and in
coronary blood vessels. Nitroglycerin's vasodilator effect
occurs through 1,2-glyceryl dinitrate and nitrite formation
by means of the mitochondrial enzyme aldehyde dehy-
drogenase (mtALDH), leading to cGMP production and
vascular smooth-muscle relaxation [115]. Even severely
atherosclerotic vessels may dilate in areas without
atheroma, lowering systolic blood pressure and dilating
systemic veins, thus reducing myocardial wall tension, a
major determinant of myocardial O2 need. Sublingual
nitroglycerin is administered for an acute attack or for pre-
vention before exertion. Dramatic relief usually takes
place within 1.5–3 minutes, is complete at 5 minutes, and
lasts up to 30 minutes. The dose may be repeated q 4–5
minutes up to three times if relief is incomplete.
Long-acting nitrates (oral or transdermal [t.d.]) are used if
symptoms persist after the β-blocker dose is maximized. If
angina occurs at predictable times, a nitrate is adminis-
tered to cover these times [116]. Nitroglycerin patches
slowly release the drug for a prolonged effect; exercise
capacity improves 4 hours after patch application and
wanes in 18–24 hours. Nitrate tolerance may occur, espe-
cially when plasma concentrations are maintained con-
stant. The most frequent side effects of nitroglycerin
patches are low blood pressure (4%), postural low blood
pressure, crescendo angina (2%), tachycardia, flushing,
peripheral edema, headache, lightheadedness, syncope
(4%), dizziness, nausea, vomiting, blurred vision, and
diaphoresis [117].Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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Nitroglycerin as anticancer agent
It is well known that hypoxia confers resistance to com-
mon cancer therapies; however, it has also has been
shown to result in genetic changes which may allow a sur-
vival advantage and increase the tumorigenic properties of
cancer cells. Additionally, it may exert a selection pressure,
allowing tumor cell expansion with a more aggressive
phenotype. This adaptation is most likely a multifactorial
process involving coordination of various stress-induced
signaling pathways, including those regulated by hypoxia-
inducible factor-1 and nuclear factor kappaB together
with their resistance mechanism-linked downstream tar-
gets [118].
Experimental data suggest that treatment of several
human cancer cells with nitric oxide and NO mimetic
agents can effectively restore the sensitivity of resistant
populations to the cytotoxic effects of chemotherapeutics
both in vitro and in vivo [119-122]. To date, the specific
mechanisms through which NO restores sensitivity to
anticancer agents are not clearly understood. Potential
mechanisms contributing to NO chemosensitizing activ-
ity include vascular changes that promote increased blood
delivery and tumor oxygenation, antioxidant effects, and
glutathione detoxification/redox buffering-system down-
regulation, inhibition of key transcription factors such as
HIF-1 and NF-kappaB, as well as drug efflux-transporter
and DNA repair-enzyme inhibition [123].
NO exerts the majority of its physiological effects by bind-
ing to its guanylyl cyclase-coupled receptors in a special-
ized heme group, the occupation of which results in
conformational changes that trigger GC activity. Thus,
generation of cyclic GMP from GTP then engages various
downstream targets including protein kinases, phos-
phodiesterases, and ion channels, giving rise to modifica-
tions in cell functions such as smooth muscle relaxation,
platelet disaggregation, and synaptic plasticity. NO also
regulates a wide range of biological functions via post-
translational protein modification [124]. Therefore, NO's
biological activities can be divided into cGMP-dependent
and cGMP-independent pathways. cGMP formation is
considered the main physiological signaling NO pathway
[125].
The three principal cGMP targets are protein kinase G,
cyclic-nucleotide-gated channels, and cyclic nucleotide
phosphodiesterase [126,127]. A recent study showed that
the cancer cell chemosensitivity-mediating via is the NO
signaling pathway involving cGMP production and subse-
quent PKG activation, and that suppression of endog-
enous NO production (hyponitroxia) appears to be a key
component of the underlying mechanism of hypoxia-
induced drug resistance in cancer cells [128]. This concept
is supported by several lines of evidence, such as that L-
arginine conversion into L-citrulline, that NO requires
molecular oxygen [129], and that exposure to low O2 lev-
els (1–3%) inhibits NO production by up to 90% in
endothelial cells and macrophages [130,131]. Further-
more, cGMP production is markedly decreased in hypoxia
(0.5% O2)-incubated tumor cells for 24 hours [132].
Hypoxia has also been shown to increase arginase activity
in macrophages [133], thus diverting L-arginine metabo-
lism away from the NO generation pathway and into the
urea cycle.
This experimental evidence was the basis for a double-
blind phase II randomized study in which 120 patients
with stage IIIB/IV NSCLC were randomly assigned to
vinorelbine 25 mg/m2 on days 1 and 8 and cisplatin 80
mg/m2 on day 1, with t.d.-applied nitroglycerin (25 mg/
patient daily for 5 days; arm A) or with placebo patch
(arm B) every 3 weeks for a maximum of four cycles. Trial
results indicate that nitroglycerin was able to increase the
response rate significantly (72 vs. 42%), which was
reflected in longer median-time-to-progression (327 vs.
185 days). It is noteworthy that there no severe side effects
except for grade 1- and -2 headaches in patients treated
with nitroglycerin arm [134]. Currently, a phase III trial is
ongoing to confirm these results.
Alpha1-adrenoceptor antagonists as antihypertensives
Alpha1 adrenergic blocking drugs are effective in reducing
blood pressure and accomplish this in a fashion compara-
ble to the majority of other antihypertensive drug classes.
These agents reduce blood pressure incrementally when
combined with other antihypertensives and are the sole
antihypertensives that improve plasma lipid profile,
decrease blood viscosity and increase red-blood-cell
deformability and endothelial function as well [135,136].
Prazosin was marketed in 1976 followed by doxazosin
and terazosin, which are once-daily dosed and more
recently, administered in a sustained release preparation.
Two additional antihypertensives, tamsulosin and alfu-
zosin, are relatively uro-selective agents and are com-
monly administered to patients with benign prostatic
hypertrophy [137]. Doxazosin also inhibits human vascu-
lar smooth-muscle cell proliferation and migration, inde-
pendent of α1-adrenoceptor blockade [138]. Alpha1-
adrenergic-specific antagonists inhibit norepinephrine's
vasoconstrictor effect. They do so by selectively inhibiting
post-synaptic α1 receptor activation by circulating and/or
neurally released catecholamines, but do not inhibit pres-
ynaptic α2-adrenergic receptors; therefore, inhibition of
additional norepinephrine release by an α2-adrenergic
receptor stimulation feedback mechanism is preserved.
Alpha1-adrenergic-specific antagonists do not interfere
with the renin-angiotensin-aldosterone system [139]. The
most troublesome side effect with α1-adrenergic antago-
nists has been first-dose low blood pressure or syncope,Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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most frequently observed with shorter-acting agents, in
volume-depleted states, and with higher doses of these
compounds. Other side effects are uncommon; these
drugs may produce urinary incontinence in women, but
this is reversible on withdrawal of the drug. In general, α1-
adrenergic antagonists should be used cautiously in chil-
dren or during pregnancy [140,141].
Currently, α1-adrenergic antagonists are no longer consid-
ered suitable initial drugs for uncomplicated early-stage
high blood pressure according to several guideline-gener-
ating groups, due to Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) find-
ings. In this trial, the doxazosin-treatment arm of the
study was terminated early, because increased cardiovas-
cular endpoints were observed when compared with chlo-
rthalidone. There was a 19% excess stroke incidence with
doxazosin and a highly significant increase (25%) in com-
bined cardiovascular disease [142,143].
alpha1-adrenoceptor antagonists as anticancer agents
It has long been hypothesized that epinephrine levels are
acute and chronically elevated in response to acute or sus-
tained stress and that such an increase is implicated in
stress-related immunosuppression pathogenesis, which in
turn may increase tumor incidence and promote meta-
static growth [144,145]. However, despite that alpha and
beta adrenergic receptors are expressed in malignant
tumor tissues and that stimulation by catecholamines
may exert a tumor growth effect [146-152], convincing
evidence of their role in tumorigenesis continues to be
lacking.
Both alpha and beta adrenergic receptors stimulate several
cAMP-mediated pathways through receptor coupling to
GTP-binding protein Gs [153,154]. Alpha adrenoceptors
have been divided into α1 and -2 receptors. Multiple α1
and -2-adrenoceptor subtypes exist. Relevant to this dis-
cussion, three α1 adrenoceptor subtypes have been cloned
and are designated α1a, -1b, and α-1d. Alpha1 adrenocep-
tors are localized postsynaptically in nerve terminal-adja-
cent smooth muscle. After extensive characterization of
cloned and native receptors in diverse tissues, it remains
difficult to ascribe a definite clinical purpose to each α1
adrenoceptor subtype beyond the role of α1 adrenoceptor
stimulation in the BPH symptom profile [139].
The realization that alpha1 adrenergic antagonists may
play a role in cancer therapy arose from observations that
doxazosin and terazosin induce prostate cancer apoptosis.
It has been demonstrated that treatment of prostate cancer
cells with doxazosin or terazosin results in significant cell-
viability loss via apoptosis induction in a dose-dependent
manner, without affecting the cell proliferation rate. Inter-
estingly, exposure to phenoxybenzamine, an irreversible
alpha1-adrenoceptor inhibitor, does not abrogate the
apoptotic effect of doxazosin or terazosin against human
prostate cancer or smooth muscle cells, suggesting that
doxazosin and terazosin apoptotic activity against pros-
tate cells is independent of their capacity to antagonize
alpha1-adrenoceptors. Furthermore, an in vivo efficacy
trial demonstrated that doxazosin administration (at tol-
erated pharmacologically relevant doses) in Severe com-
bined immunodeficient (SCID) mice bearing PC-3
prostate cancer xenografts resulted in significant tumor
growth inhibition [155,156]. The proapoptotic effect of
doxazosin results from Bax and Fas/CD95 up-regulation
and Bcl-xL and TRAMP/Apo3 down-regulation as shown
in a global expression assay, and can be blocked by spe-
cific caspase-8 inhibitors as doxazosin increases Fas-asso-
ciating death domain-containing protein (FADD)
recruitment and subsequent caspase-8 activation, impli-
cating Fas-mediated apoptosis [157]. In addition, doxa-
zosin inhibits human vascular endothelial cell adhesion,
migration, and invasion in human endothelial cells [158].
In a recent study among several quinazoline-based
alpha1-adrenoceptor antagonists, prazosin displayed anti-
proliferative activity superior to that of other alpha1-
blockers including doxazosin, terazosin, tamsulosin, and
phentolamine. Prazosin induces cell apoptosis through
induction of DNA damage stress, leading to Cdk1 inacti-
vation and G2 checkpoint arrest, as well as mitochondria-
mediated apoptosis. In vitro antitumor effects are also
observed in vivo with oral administration of prazosin in
PC-3-derived cancer xenografts in nude mice [159].
More recently, doxazosin has been reported to inhibit
proliferation and induce apoptosis in breast cancer cells in
vitro  in alpha1-adrenergic receptor-independent mecha-
nisms. Intriguingly, doxazosin treatment reduced phos-
phorylated EGFR expression, decreased pERK1/2 levels,
and decreased NF-kB, AP-1, SRE, E2F and CRE-mediated
transcriptional activity. These effects cannot be blocked by
EGF- and TNFa-treatment alone, but by the combination
of EGF and TNFa treatments, indicating that doxazosin
inhibits both EGFR and NF-kB signalling pathways to
induce breast cancer cell apoptosis [160]. Taken together,
the evidence challenges conventional knowledge of the
mechanism of action of alpha1-adrenoceptor antagonists
and points to a new therapeutic value for these drugs by
providing a differential molecular basis for their anti-
tumor efficacy. The fact that the majority of alpha1-adren-
ergic antagonists are quinazoline-based drugs such as gef-
initib and that doxazosin treatment reduces
phosphorylated EGFR and phosphorylated ERK levels –
effects that overlap with those induced by gefitinib [160]
– suggest that these inexpensive drugs could be as effective
as current EGFR inhibitors and merit clinical testing.Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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Hydralazine as antihypertensive and vasodilator
Hydralazine, a potent arterial vasodilator that reduces
peripheral resistance directly by relaxing the smooth mus-
cle cell layer in arterial vessels, has long been utilized for
management of hypertensive disorders and heart failure;
nonetheless, its current use is limited nearly to hyperten-
sive disorders during pregnancy. Despite numerous stud-
ies conducted with the drug, its mechanism of action has
remained unknown. Notwithstanding this, it has been
suggested that hydralazine may function by either modu-
lating the effect of sympathetic nerve ending-released
purine-like compounds and/or by producing an altered
Ca2+ balance in vascular smooth muscle cells [161-164].
Hydralazine is well absorbed through the gastrointestinal
tract, but systemic bioavailability is low. Because the
acetylated compound is inactive, the dose required to pro-
duce a systemic effect is higher in fast acetylators. N-
acetylation of hydralazine occurs in bowel and/or liver.
Hydralazine's half-life is 1 hour and systemic clearance of
the drug is approximately 50 mL/kg/min. Systemic metab-
olism is dependent on hydroxylation followed by conju-
gation with glucoronic acid in liver, which is not
dependent on acetylation rate; therefore, half-life does not
differ to a great degree between slow and fast acetylators
[165]. Hydralazine peak concentration in plasma and the
drug's peak hypotensive effect occurs within 30–120 min-
utes of ingestion. Although its half-life in plasma is
approximately 1 hour, duration of the hypotensive effect
can last as long as 12 hours. Hydralazine's antihyperten-
sive effect possesses no clear dose-response effects. The
dose varies from 10 mg four times a day to 50 mg four
times daily. After stabilization with multiple daily doses,
a twice-daily dose regimen can be effective. Slow acetyla-
tors require a lower dose. For heart failure, recommended
doses are higher (up to 800 mg daily or more); as a rule,
10–100 mg four times a day can be effective [166]. Com-
mon side effects include headache, nausea, flushing, low
blood pressure, palpitation, tachycardia, dizziness, and
angina pectoris. Hydralazine causes autoimmune reac-
tions, among which the drug-induced lupus-like syn-
drome is the most common [161].
Hydralazine as anticancer agent
The first observations on DNA demethylation as a
hydralazine off-target effect were performed in 1988 in
the course of experiments to prove that this drug could
induce self-reactivity in cloned T-cell lines and DNA
hypomethylation [167], followed by reports on its ability
to restore expression of tumor suppressor genes silenced
by promoter hypermethylation in cancer cell lines and
primary tumors [168-171]. In silico models have demon-
strated that residues Lys162 and Arg 240 within the
enzyme active site interact with hydralazine at distances
between these residues and hydralazine nitrogen atoms
not exceeding 4A°. These interactions are energetically
stable, supporting that hydralazine may inhibit DNA
methyltransferase [172].
Contrariwise, other authors have reported that hydrala-
zine decreases DNA methyltransferase 1 and 3a expres-
sion in a similar manner to PD98059, a Mitogen-activated
protein kinase kinase (MEK) inhibitor, this suggesting
that hydralazine does not directly inhibit DNA methyl-
transferase enzymatic activity [173]. These discrepancies
with regard to hydralazine's precise mechanism of action
as DNA methylation inhibitor extends to other non-nucl-
eoside DNA methylation inhibitors, which may stem
from technical issues [174]; hence, this issue concerning
hydralazine's mechanism of action needs to be further
addressed. The pre-clinical and clinical development of
this agent has been performed in combination with valp-
roic acid [175]. Currently, hydralazine alone is being
tested as demethylating in breast and colorectal cancer,
and in combination with valproate is in phase III trials in
cervical and ovarian carcinomas.
Procainamide as antiarrhythmic
Procainamide is a group 1A cardiac antiarrhythmic drug
available in oral and i.v. preparations. By blocking Na+
channels, class I drugs primarily block the rapid inward
sodium current, thereby slowing the action-potential rise
rate. Procainamide increases the atria's effective refractory
period, and to a lesser extent, the His-Purkinje system
bundle and heart ventricles. Therapeutic procainamide
levels may exert vagolytic effects and produce slight heart
rate acceleration, while high or toxic concentrations may
prolong A-V conduction time, or induce AV block, or even
cause abnormal automaticity and spontaneous firing, by
unknown mechanisms [176]. Procainamide is well
absorbed following oral administration. The absolute bio-
availability is approximately 85% in patients and healthy
subjects. Plasma protein binding of procainamide is insig-
nificant, approximately 20%. The apparent distribution
volume is approximately 2 L/kg. Procainamide's elimina-
tion half-life is 3–4 hours in patients with normal renal
function, but reduced renal function prolongs the half-
life. Procainamide is mainly eliminated intact by the kid-
neys. The only metabolite of any significance comprises
N-acetylprocainamide (NAPA), which is mainly excreted
by the kidney. NAPA plasma concentration is lower than
the PA concentration in the majority of individuals. The
reverse may occur in individuals who form more of the
metabolite while also having reduced kidney function.
NAPA has significant antiarrhythmic activity. An average
of 65% of the dose was recovered as intact drug in urine
after i.v. PA administration. Active renal secretion is the
major elimination pathway for procainamide and utilizes
the base-secreting system responsible for secretion of met-
formin, cimetidine, ranitidine, triamterene, and flecain-Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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ide; thus, there is a potential for drug-drug interactions at
this level [177,178]. This drug is currently indicated for
treatment of atrial fibrillation and is second choice for
sustained ventricular arrhythmia management (in the
acute MI setting). It is also effective in suppression of pre-
mature ventricular contractions and paroxysmal ventricu-
lar tachycardia rapidly following i.v. administration.
Among its side effects, nausea and vomiting are common
[179-181]. Like hydralazine, its long-term use is associ-
ated with drug-induced, reversible lupus erythematosus-
like syndrome, which occurs at a frequency of 25–50%.
Positive antinuclear antibody test is common, although
symptoms disappear upon drug discontinuation. In slow
acetylators, the procainamide-induced lupus syndrome
takes place more frequently and earlier in therapy than in
rapid acetylators [182].
Procainamide as anticancer agent
Clues from discovering the DNA methylation inhibitory
activity of this drug, as from hydralazine, derived from its
lupus-like properties in experimental lupus systems [183].
Afterward, in 2001 Lin et al. reported that procainamide
was able to demethylate and restore GSTP1 gene expres-
sion in LNCaP prostatic carcinoma cell line in vitro and in
nude mice carrying prostatic carcinoma xenografts [184].
These effects of procainamide were also confirmed in
additional genes and cell lines as reported for hydralazine
[168]. Subsequently, it was reported that procainamide
specifically inhibits hemimethylase activity of DNA meth-
yltransferase 1 (DNMT1), the mammalian enzyme
thought responsible for maintaining DNA methylation
patterns during replication. At micromolar concentra-
tions, procainamide was found as a partial competitive
DNMT1 inhibitor, reducing the enzyme's affinity for its
two substrates: hemimethylated DNA, and S-adenosyl-l-
methionine. By doing this, procainamide significantly
decreased DNMT1 processivity on hemimethylated DNA.
Procainamide was not a potent inhibitor of de novo meth-
yltransferases DNMT3a and -b. As further evidence of pro-
cainamide's specificity for DNMT1, procainamide failed
to lower genomic 5-methyl-2'-deoxycytidine levels in
HCT116 colorectal cancer cells when DNMT1 was geneti-
cally deleted, but significantly reduced genomic 5-methyl-
2'-deoxycytidine content in parental HCT116 cells and in
HCT116 cells in which DNMT3b was genetically deleted
[185]. No clinical studies of procainamide as demethylat-
ing agent are reported.
Local anesthetics
Procaine as local anesthesic
Procaine is a local anesthetic drug of the amino ester
group that was introduced in 1905 and became the first
local anesthetic to gain wide acceptance in the U.S. None-
theless, its popularity as a local anesthetic declined after
the introduction of lidocaine in 1948, which is the most
frequently used local anesthetic at present. Procaine is cur-
rently used primarily to reduce the pain of intramuscular
injection of penicillin and is also used in dentistry. Local
anesthetics block nerve-impulse generation and conduc-
tion, presumably by increasing the nerve's electrical exci-
tation threshold by slowing propagation of the nerve
impulse and by reducing the action-potential rise rate
[186]. Systemic absorption of local anesthetics produces
effects on the cardiovascular and central nervous systems.
At blood concentrations achieved with normal therapeu-
tic doses, changes in cardiac conduction and peripheral
vascular resistance are minimal. Nevertheless, toxic blood
concentrations depress cardiac conduction and excitabil-
ity, which may lead to atrioventricular block and ulti-
mately, to cardiac arrest. In addition, myocardial
contractility is depressed and peripheral vasodilation
occurs, leading to decreased cardiac output and arterial
blood pressure. At the central nervous system, local anes-
thetics can produce stimulation, depression, or both,
manifested by restlessness, tremors and shivering, convul-
sions, followed by depression, and coma progressing ulti-
mately to respiratory arrest [187,188]. Depending on the
administration route, local anesthetics are distributed to
some extent to all body tissues and bind plasma proteins
at varying degrees. Several pharmacokinetic parameters of
local anesthetics can be significantly altered by the pres-
ence of hepatic or renal disease, addition of epinephrine,
factors affecting urinary pH, renal blood flow, the drug
administration route, and age of the patient. [189].
Procaine as anticancer agent
Procaine, like procainamide, is a derivative of 4-ami-
nobenzoic acid, but the former is the ester with 2-(diethyl-
amino) ethanol, while the latter is the amide with 2-
(diethylamino) ethylamine. Its demethylating activity,
therefore, was suggested by its structural analogy to pro-
cainamide, and was demonstrated in 2003 by Villar-Garea
et al., who reported that procaine leads to global genomic
DNA hypomethylation and demethylation and reactiva-
tion of tumor suppressor genes with hypermethylated
CpG islands in MCF-7 breast cancer cells. These effects of
procaine are associated with growth inhibitory effects in
these breast cancer cells. Although that procaine inhibits
DNA methyltransferase activity was not demonstrated, it
probably does, because procaine, like procainamide,
binds strongly to CpG-rich DNA [190]. Procaine has also
shown to inhibit growth and to reactivate the expression
of RASSF1A mRNA in nasopharyngeal cancer cell lines
[191], as well as to reactivate estrogen receptor-gene
expression in MCF-7 breast cancer cells [192]. No clinical
studies of procaine as demethylating agent are reported;
instead, analogs of this drug are pursued to exploit its
demethylating activities [193].Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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Antiepileptics
Valproic acid as antiepileptic
Valproic acid (VPA) is a small, branched fatty acid whose
chemical properties allow easy delivery to the organism
and cells. It is slightly soluble in water, highly soluble in
organic solvents, and stable at room temperature. Because
valproic acid exists in a dissociated form in alkali metal-
containing water solutions, it can be easily delivered to
organisms in the form of sodium or magnesium salts,
which are water soluble. Yet the two preparations are
bioequivalents; magnesium valproate appears to be a
drug without bioavailability problems and with reduced
intersubject variability, compared with that of sodium val-
proate [194]. Valproic acid is now an established drug for
treatment of epileptic seizures and mania in bipolar disor-
der. In the human brain, valproic acid affects neurotrans-
mitter GABA function by potentiating GABA inhibitory
activity by several means, including inhibition of GABA
degradation, increased GABA synthesis, and decreased
GABA turnover. It was also found to attenuate NMDA-
mediated excitation, block voltage-dependent Na+ chan-
nels, and modulate neuron firing frequency [195,196].
VPA is rapidly absorbed after oral administration, with
peak serum levels occurring approximately 1–4 hours
after a single oral dose. Valproic acid half-life in serum
falls typically within the range of 7–16 hours. When the
drug is administered with meals, a slight delay in absorp-
tion occurs, but this does not affect total absorption. VA
distribution throughout the body is rapid. The drug is
strongly bound (95%) to human plasma proteins.
Decreases in the extent of protein binding and variable
changes in valproic acid clearance and elimination may
result from dosage increases. As an antiepileptic, the ther-
apeutic plasma concentration is believed to range from
50–100 μg/mL. VPA is primarily metabolized to the glu-
coronide conjugate in the liver. Only very little unmetab-
olized parent drug is excreted in urine. VPA and its
metabolites are eliminated mainly in urine, with minor
amounts appearing in feces. VPA is in general well toler-
ated by patients. Neurological side effects such as seda-
tion, dizziness, and tremor, as well as mild
gastrointestinal toxicities, usually take place early during
treatment [195-197]. The most serious adverse events are
liver failure and teratogenicity. Fatal hepatotoxicity is rare
(approximately 1:15,000) and principally occurs in chil-
dren aged < 2 years treated with multiple drugs. It can
induce birth defects such as neural tube closure defects
and other malformations when administered during early
pregnancy. Teratogenicity and antiepileptic activity
appear to require different mechanisms of action, because
molecule modifications generate selective compounds
with either teratogenic or antiepileptic activity [198,199].
Valproic acid as anticancer agent
The finding that VPA was an effective inhibitor of HDACs
arose from observations that valproic acid was able to
relieve transcriptional repression of a peroxisomal prolif-
eration and activation of a glucocorticoid receptor (GR)-
PPARδ hybrid receptor and a RAR-dependent reporter
gene expression system, suggesting that VPA acts on a
common factor in gene regulation, such as co-repressor-
associated HDACs, rather than on individual transcrip-
tion factors or receptors. Consistent with this finding, it
was shown that VPA causes N-terminal tail hyperacetyla-
tion of histones H3 and -4 in vitro and in vivo and was
proven to inhibit HDAC enzymatic activity directly at a
VPA concentration of 0.5 mM [200].
Simultaneously, Phiel et al., after demonstrating VPA's
ability to activate multiple promoter-regulated transcrip-
tion, assayed HDAC1 activity in the presence of VPA in
HeLa cells that over-expressed HDAC1. As expected, VPA
inhibits HDAC1 in vitro in a dose-dependent manner,
with an of 0.4 mM, falling within the therapeutic range for
VPA therapy in humans. The authors also demonstrated
that VPA inhibits HDACs other than HDAC1, including
HDAC1, -2, -3, -4, and -8 with a 50% inhibition between
0.5 and 2 mM. VPA-induced hyperacetylation of H4 and
non-histone proteins such as p53 was also demonstrated
at concentrations as low as 1–2 mM [201]. Later, employ-
ing a series of compounds with structural similarity to
VPA, Gurvich et al. found that VPA inhibits class I HDACs
(HDACs 1–3) with IC50 values ranging from 0.7–1 mM
and inhibits class II subclass I HDACs 4, -5, and -7 with
IC50 values ranging from 1–1.5 mM; to the contrary, VPA
does not inhibit HDAC 6 or -10 (class II subclass II). Inter-
estingly, relative VPA-analog potencies to inhibit HDACs
correlated with their potencies in inducing leukemia cell-
line differentiation, which led the authors to conclude
that VPA effects on differentiation are most likely due to
inhibition of HDACs [202]. Further, it has additionally
been shown that VPA alters the expression of genes that
regulate chromatin structure. VPA in breast cancer cells
induces a depletion of several members of structural
maintenance of chromatin (SMC) proteins, SMC-associ-
ated proteins, DNA methyltransferase, and heterochroma-
tin proteins, which lead to chromatin decondensation,
enhanced DNA sensitivity to nucleases, and increased
DNA interaction with intercalating agents. This modula-
tion is not a direct – but is rather a downstream – effect of
histone acetylation reversible upon drug withdrawal
[203].
VPA has shown potent antitumor effects in a variety of in
vitro and in vivo systems by modulating multiple pathways
including cell cycle arrest, apoptosis, angiogenesis, metas-
tasis, differentiation, and senescence. These effects appear
to be cell type-specific, which may also depend on the dif-Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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ferentiation level and the underlying genetic alterations
[204,205]. In addition, whole genome expression by
microarray analysis from primary tumors of VPA-treated
patients demonstrate significant up-regulation of hun-
dreds of genes belonging to multiple pathways including
ribosomal proteins, oxidative phosphorylation, MAPK
signaling, focal adhesion, cell cycle, antigen processing
and presentation, proteasome, apoptosis, PI3K, Wnt sign-
aling, calcium signaling, TGF-beta signaling, and ubiqui-
tin-mediated proteolysis, among others [175]. Currently,
there are several clinical phase I and II studies reported
that show that valproic acid induces histone hyperacetyla-
tion and HDAC activity inhibition in both tumors and the
peripheral blood of patients, and when associated with
chemotherapy exhibits encouraging antitumor responses
in a range of solid tumors and malignant hematological
diseases. In addition, a number of clinical trials are ongo-
ing with VPA in combination with DNA methylation
inhibitors, classical cytotoxics, newer targeted agents, and
radiation [175,206].
Topiramate, levetiracetam, and carbamazepine
The finding that VPA is an HDAC inhibitor led researchers
to assess comparatively the activity of traditional and
newer AEDs such as HDAC inhibitors in HeLa cells by
immunoblot utilizing an acetylated histone H4-specific
antibody, and by direct HDAC inhibition employing
HeLa nuclear extract as an HDAC source and an acetylated
lysine substrate. Results disclosed that the HDAC inhibi-
tory capacity of AED is not limited to VPA, but is also
shown by topiramate and a levetiracetam metabolite
[207]. Although in this system carbamazepine failed to
show HDAC inhibition, in a subsequent report this drug
induced histone H4 acetylation in the HepG2 liver carci-
noma cell line and inhibited HDAC 3 and -7, which are
representative of HDAC class I and II, respectively. Quan-
titative testing in an in vitro assay demonstrated HDAC
inhibition with an IC50 of 2 μM. The major active metab-
olite of CBZ, CBZ-10,11-epoxide, was found to have the
same HDAC inhibitory activity. It is noteworthy that the
IC50 of 2 μM is considerably lower than therapeutic
plasma levels typically achieved in patients (range, 25–51
microM) [208]. The potential antitumor properties of
these HDAC inhibition-derived AED have not been fur-
ther pursued but this novel off-target effect should not be
neglected in cancer research.
Antidiabetic agents
Thiazolidinediones (TZDs) as antidiabetic drugs
TZDs are a relatively new class of oral agents that have rap-
idly gained wide usage, with an estimated 20 million pre-
scriptions written in 2004. These compounds are effective,
generally well tolerated, and complement other antidia-
betic drugs [209]. The first of this drug class, troglitazone,
was introduced in 1997, but was removed from the mar-
ket due to the occurrence of idiosyncratic liver injury
[210]. Currently rosiglitazone and pioglitazone are used
as antidiabetic agents. This novel class of drugs increases
insulin-stimulated glucose uptake by skeletal muscle cells;
therefore, these agents decrease insulin resistance in
peripheral tissues. Contrary to other antidiabetic drugs,
TZDs do not stimulate insulin secretion by pancreatic islet
cells [211,212]. In addition to their ability to lower insu-
lin levels, TZDs possess certain lipid benefits. High-den-
sity-lipoprotein (HDL) cholesterol concentrations, for
instance, increase with TZD therapy, and triglyceride con-
centrations frequently fall [213,214].
Rosiglitazone and pioglitazone appear equally effective in
achieving glycemia reductions. In controlled trials, TZDs
generally lower HbA1c to the same degree as other antid-
iabetic agents. Head-to-head comparisons have been per-
formed on TZDs vs. metformin and sulfonylureas, with
similar reductions in HbA1c [215-217]. TZDs also have a
number of anti-atherogenic effects independent of their
influences on glucose and insulin metabolism. These
improve lipid profiles, lower blood pressure, possess anti-
inflammatory properties, improve endothelial function,
and increase large artery compliance in patients with type
2 diabetes mellitus (DM2) [218,219].
Adverse effects of TZDs include weight gain, which
appears to involve mainly peripheral subcutaneous sites,
with a reduction in visceral fat depots, the latter better cor-
related with insulin resistance. Edema can also occur.
Both weight gain and edema are more common in
patients who receive TZDs with insulin. Anemia may also
occur infrequently. TZDs, unlike troglitazone, have not
been convincingly associated with liver injury. Patients
with advanced congestive heart failure and those with
hepatic impairment should not receive TZDs. Recent stud-
ies in rodent models indicate that exposure to TZD
reduces bone mass compared with controls [220-222].
Thiazolidinediones as anticancer agents
Peroxisome proliferation activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily of
ligand-activated transcription factors related with retin-
oid, steroid, and thyroid hormone receptors [223]. The
PPAR subfamily consists of three members: PPAR-α; -δ
(also known as β), and -γ, which have a similar structural
organization. An N-terminal region responsible for lig-
and-independent activation followed by a DNA-binding
domain of two zinc fingers separated by a linker region
and the C-terminal ligand-binding domain [224,225].
The name PPARs derives from the observation that activa-
tion by xenobiotics of the first receptors to be character-
ized, PPAR-α, results in peroxisome proliferation in
rodent hepatocytes.Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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PPAR-δ or -γ isoform activation, however, does not elicit
this response. The majority of tissues in humans express
all three receptor subtypes, although there is considerable
variability in relative expression levels. PPAR-δ is
expressed ubiquitously in all adult mammal tissues,
whereas two PPAR-γ isoforms, γ1 and -2, which arise from
alternative promoter usage and differential splicing, are
preferentially expressed in adipose tissue. PPARs regulate
gene expression by binding as heterodimers with retinoid
× receptors (RXRs) to specific response elements (PPREs)
in target-gene promotor regions. In the absence of PPAR
gamma ligands, which include long-chain polyunsatu-
rated fatty acids, eicosanoid derivates, and oxidized lipids,
high-affinity complexes are formed between the PPAR-
RXR heterodimer and nuclear receptor co-repressor pro-
teins. These prevent transcriptional activation by seques-
tration of the nuclear receptor heterodimer from the
promoter. The co-repressors dissociate as a consequence
of ligand binding-induced conformational change, and
the activated heterodimer can bind to PPREs. Both the sol-
uble and DNA-bound PPAR-RXR heterodimer then recruit
co-activator proteins in a ligand-dependent fashion that
couples the receptor complex to other transcriptional-
machinery components [226-228].
The anti-proliferative, proapoptotic, and differentiation
effects of PPAR-γ activators suggest that these compounds
might be useful as anticancer therapy. In support of this
hypothesis, TZDs exhibit in vitro and in vivo antitumor
effects on a number of malignancies including breast,
lung, glioblastoma, thyroid, and urological- and gastroin-
testinal organ-derived malignancies [229-232]. Further-
more, PPAR-γ ligands have been shown to be potent
angiogenesis and metastasis inhibitors [233-236]. Never-
theless, it remains poorly understood how PPARs γ affects
malignant tumors, because they exert pleiotropic effects
on cell fate and metabolism and may act both as neopla-
sia promoter and suppressor. In fact, and paradoxically,
recent studies have shown that PPAR-γ inhibition by
PPAR-γ-specific antagonists also induce cell death, apop-
tosis, and anoikis and inhibit tumor cell invasion [237-
239].
PPAR-γ activation antitumor effects by ligands appear to
be mediated by means of both PPARγ-dependent and -
independent (off-target) pathways, depending on agonist
type, concentration, and tumor cell type [240]. In addi-
tion, it appears that TZDs possess inhibitory effects not
only on tumors cells, but also on stromal cells, such as
smooth muscle, endothelial, and inflammatory cells,
which explain observations on minimal-to-no inhibitory
activity on some tumor cell lines in vitro but potent inhi-
bition of these tumors in vivo [235]. Antitumor effects by
a PPARγ-independent (off-target) pathway and/or a
biphasic effect have also been suggested [241]. While the
PPARγ agonist 15d-PGJ2 increases transcriptional activity
and CD36, the antagonist GW9662 reduces this but does
not block agonist-induced apoptosis in breast cancer cells.
In addition, the GW9662 antagonist enhances the agonist
rosiglitazone's inhibitory effect on breast cancer cells
rather than rescuing tumor growth, suggesting that PPARγ
activation may not be involved in TZD-caused survival
and cell growth inhibition. Similar results were obtained
in studies in which PC3, CaCO-2, and T47D cancer cells
were inhibited by both PPARγ agonists and antagonists
separately and in co-treatments [242,243]. This apparent
paradoxical synergism between agonists and antagonists
is in line with the finding that while PPARγ agonists can
possess tumor suppressing effects, antagonists also can
induce apoptosis in cancer cells [237-239].
These experimental findings have been translated into
early clinical trials beginning with a successful clinical
report on three cases of patients with intermediate-to-
high-grade liposarcoma in whom troglitazone adminis-
tration induced histologic and biochemical differentia-
tion  in vivo as shown by extensive tumor-cell lipid
accumulation and substantial NMR-detectable tumor trig-
lyceride increases compared with pretreatment biopsies,
accompanied by marked reduction in Ki-67 expression
[244].
Subsequently, however, clinical trials in patients with
liposarcoma, advanced breast, and colorectal tumors
demonstrated no clinical response using troglitazone or
rosiglitazone [245-247]. Nonetheless, additional clinical
data demonstrate that short-term rosiglitazone therapy in
patients with early-stage breast cancer leads to local and
systemic effects on PPARγ signaling [248], as well as radi-
oiodine uptake in some patients with thyroglobulin-posi-
tive and radioiodine-negative differentiated thyroid
cancer [249].
Metformin as antidiabetic drug
Metformin is an oral antihyperglycemic agent that has
been widely used in non-insulin-dependent diabetes mel-
litus management. Considered an insulin sensitizer
because it lowers glucose levels without increasing insulin
secretion, metformin is distinguished from thiazolidine-
diones by its primary site of action. Metformin lowers
endogenous glucose production at the level of the liver,
while thiazolidinediones work primarily in peripheral tis-
sues such as muscle and fat [250]. Thus, metformin's glu-
cose lowering effect results from a 25–30% endogenous
glucose-rate decrease, which is entirely accounted for by
reduction in the rate of gluconeogenesis [251].
Decreased hepatic gluconeogenesis can occur by hepatic
lactate uptake inhibition [252], although other studies
have found that metformin decreases gluconeogenic fluxMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
Page 16 of 33
(page number not for citation purposes)
through pyruvate carboxylase inhibition, phosphoe-
nolpyruvate carboxykinase activity, and, possibly through
increased conversion of pyruvate to alanine [253]. In
addition, metformin also stimulates AMP-activated pro-
tein kinase (AMPK) in intact cells and in vivo, and possi-
bly inhibits complex 1 of the mitochondrial respiratory
chain. AMPK is the downstream component of a protein
kinase cascade that acts as a cellular energy sensor. Once
activated by ATP depletion, this turns ON ATP-producing
catabolic pathways and switches OFF ATP-consuming
anabolic pathways, both directly via metabolic enzyme
phosphorylation and indirectly via gene expression
effects. Metformin stimulates phosphorylation of a key
regulatory site in the AMPK catabolic subunit in intact
cells [254,255].
The oral bioavailability of this drug ranges between 40
and 60%; it is primarily excreted unchanged in urine with
neligible metabolism [256]; approximately 20–30% of
the drug is recovered unchanged in feces [257]. It is
mainly absorbed in the upper part of the intestine, and
estimated time for its complete absorption is approxi-
mately 6 hours [256]. Clinical trials with metformin have
demonstrated decreased bioavailability at higher doses,
suggesting saturable intestinal absorption [256,258]. Met-
formin is the first-line pharmacotherapy in the treatment
of overweight or obese patients with DM2, with beneficial
effects on weight in this population in that metformin
exerts a positive effect on metabolic parameters such as
waist circumference, fasting insulin, glucose levels, and
triglycerides [259]. Excess-weight disorders are character-
ized by an increased mass of adipose tissue. The foremost
physical consequences comprise impaired glucose toler-
ance, white-coat hypertension or high blood pressure,
dyslipidemia, and coronary heart disease [260]. Some
authors have suggested a benefit role of metformin in the
treatment of excess weight and associated disorders
[261,262]. Metformin has also been utilized as treatment
in Polycystic ovary syndrome (POS), achieving promising
results in terms of normalization of LH/FSH ratio, fasting
insulin, testosterone, and progesterone levels, and/or
pregnancy [263]. Metformin is usually well tolerated and
the most frequent side effects comprise gastrointestinal
effects including nausea, diarrhea, abdominal pain, and
anorexia. Metformin may also cause lactic acidosis, partic-
ularly in patients with renal or liver dysfunction.
Metformin as anticancer drug
The discovery of LKB1 as the tumor suppressor gene
responsible for Peutz-Jegher syndrome, an autosomal-
dominant disorder characterized by melanocytic macules
of the lips, multiple gastrointestinal hamartomatous pol-
yps, and an increased risk for various neoplasms including
gastrointestinal cancer led to the suspicion that met-
formin may exhibit antitumor properties, because LKB1 is
an upstream AMPK regulator [264]. These observations
were supported by two reports linking treatment with
metformin in patients with diabetes with a lower risk of
cancer [265,266].
A number of experimental data indicate that metformin
AMPK exerts its antitumor actions by activating AMPK.
This serine/threonine kinase consists of a heterotrimeric
complex comprising a catalytic α subunit and regulatory β
and γ subunits [267]. AMPK is activated under conditions
that deplete cellular ATP and elevate AMP levels such as
glucose deprivation, hypoxia, ischemia, and heat shock,
which are associated with an increased AMP/ATP ratio
[268]. AMPK actions appear to be mediated by means of
multiple mechanisms. AMPK activation leads to cell cycle
arrest via p53-p21 axis up-regulation, although Cyclin D1
down-regulation may also occur independently of AMPK
activation [269] and protein synthesis-regulation inhibi-
tion of the TSC2-mTOR (mammalian target of rapamy-
cin) pathway. In addition, AMPK activation impedes de
novo fatty acid synthesis, specifically the generation of
mevalonate, as well as other products downstream of
mevalonate in the cholesterol synthesis pathway. Thus,
the AMPK signalling network contains a number of tumor
suppressor genes including LKB1, p53, TSC,1 and -2, and
overcomes growth factor signalling from a variety of stim-
uli (via growth factors and by abnormal regulation of cel-
lular proto-oncogenes including PI3K, Akt, and ERK
[270].
Recent studies have reported that extracellular hormonal
stimulation by adiponectin and leptin, both of which are
adipose tissue-secreted peptide hormones, also could acti-
vate AMPK [271]. Adiponectin has been reported to
inhibit vascular SMC proliferation [272]. Plasma adi-
ponectin has been shown as decreased in patients with
carcinomas from breast, endometrium, and stomach
[273-275]. Interestingly, potential anticancer effects of
adiponectin have been demonstrated in breast and
endometrial cancer cells [276,277].
Thus, metformin exhibits pleiotropic effects on cancer
cells as reflected by its antitumor effects in a wide variety
of cancer cell lines in vitro and in vivo including breast, gli-
oma colon, ovarian, and prostate [278-281]. Whether
their antitumor actions depend on AMPK activation or
whether these are independent of this pathway requires
further study. What is clear, however, is that metformin
possesses full potential as a cancer drug that should be
fully evaluated in pre-clinical and clinical studies.
Obesity drugs
Orlistat for obesity
Obesity and overweight are highly and increasingly prev-
alent chronic conditions. In addition to lifestyle modifica-Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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tion as initial treatment, orlistat, a gastrointestinal lipase
inhibitor, sibutramine, a centrally acting monoamine
reuptake inhibitor, and rimonabant, an endocannabinoid
receptor antagonist, are approved for long-term treatment
of obesity [282].
Orlistat is a potent inhibitor of Fatty acid synthase (FAS)
activity, a key metabolic enzyme responsible for the termi-
nal catalytic step in novo fatty acid biosynthesis [283]. Orl-
istat was approved by the FDA as an antiobesity drug. It is
a semi-synthetic derivative that irreversibly inhibits pan-
creatic and gastric lipases within the gastrointestinal tract
[284]. Unlike other medicaments previously approved for
obesity treatment, orlistat does not act on the CNS;
instead, it decreases dietary fat absorption in the gastroin-
testinal tract by approximately 30% [285]. In addition to
its antiobesity effects, orlistat reduces the incidence of
DM2 mainly in patients with impaired glucose tolerance
at baseline. Compared with placebo, orlistat also signifi-
cantly reduces waist circumference, Body mass index,
Systolic blood pressure, diastolic blood pressure, fasting
glucose, and hemoglobin A1C concentrations in patients
with diabetes, and total cholesterol, Low-density-lipopro-
tein cholesterol (LDL-C), and High-density-lipoprotein
cholesterol (HDL-C) concentrations [286].
Orlistat possesses extremely low oral bioavailability, and
when co-administered with other agents, has demon-
strated no pharmacokinetic and pharmacodynamic inter-
actions with drugs such as glyburide, digoxin, warfarin,
oral contraceptives, nifedipine, and ethanol. However,
orlistat interferes with the absorption of many drugs (such
as warfarin, amiodarone, cyclosporine, and thyroxine, as
well as fat-soluble vitamins), affecting their bioavailabil-
ity and effectiveness [287].
Gastrointestinal events such as oily stools, diarrhea,
abdominal pain, and fecal spotting are common. A few
cases of serious adverse hepatic effects (cholelithiasis,
cholestatic hepatitis, and subacute liver failure) have been
reported. The majority of these events is mild to moderate
in intensity, transient in duration, and decreased consid-
erably during the second year of treatment.
Orlistat is not significantly absorbed into the systemic cir-
culation and is well tolerated. It has been also reported
that orlistat has no significant effects on calcium, phos-
phorus, magnesium, iron, copper, or zinc balance or on
bone biomarkers [288,287].
Orlistat as anticancer drug
It is now clear that cancer cells possess not only high rates
of aerobic glycolysis, high rate of energy-consuming proc-
esses driving increased DNA and protein synthesis, but
also increased de novo fatty acid (FA) synthesis, a forgotten
glycolytic pathway-related process [289]. There are two
sources of FAs for animal metabolism: Dietary FAs, and
endogenously synthesized fatty acid synthase (FASN)-cat-
alyzed FAs utilizing acetyl-CoA as primer, malonyl-CoA as
two-carbon donor, and NADPH as reducing equivalent.
The predominant product of FASN is the 16-carbon FA,
palmitate. Under normal conditions, dietary fat suffices to
fulfill requirements with the consequent under-use of
endogenous Fas [290]. Contrariwise, tumors and their
precursor lesions unexpectedly undergo exacerbated
endogenous FA biosynthesis irrespective of extracellular
lipid levels. Tumor cells can redirect the excess glycolytic
end-product pyruvate toward de novo FA synthesis, which
is necessary to maintain a constant supply of lipids and
lipid precursors to fuel membrane production and lipid-
based post-translational protein modification in a highly
proliferating cell population. This exacerbated lipogenesis
in tumor cells is reflected by the significantly increased
activity and expression of several lipogenic enzymes, of
which FASN is the key terminal catalytic step in FA synthe-
sis. Immunohistochemical studies have reported
extremely high FASN levels in many pre-neoplastic lesions
and cancers including breast, colorectum, prostate, blad-
der, ovary, esophagus, stomach, lung, oral tongue, oral
cavity, head and neck, thyroid, and endometrium, and
also in mesothelioma, nephroblastoma, retinoblastoma,
soft tissue sarcomas, melanoma, and hepatocellular carci-
noma [291,292].
FASN over-expression may actively contribute to malig-
nant-phenotype development, maintenance, and/or pro-
motion, because its inhibition by orlistat induces cell-
cycle arrest and apoptosis in a wide variety of cancer cell
lines including prostate, breast, gastrointestinal, chronic
lymphocytic leukemia, and others [293-296], suggesting a
role for FASN in the molecular integration of a number of
signalling pathways that functionally link metabolism,
proliferation, and survival in malignant cells. Second,
FASN has the ability to regulate specifically the activity
and/or expression of key cancer-related signalling net-
works of growth factors and their receptors, as well as of
steroid hormones and their receptors [291]. This is of par-
ticular relevance in breast cancer cells over-expressing
Her2 in which micromolar concentrations of orlistat are
able to down-regulate Her2 by > 90%. In addition, orlistat
in combination with trastuzumab exhibits a strong syner-
gistic antitumor effect [297,298].
Cholesterol-lowering agents
Statins as cholesterol-lowering agents
Coronary heart disease (CHD) is a major cause of morbid-
ity and mortality worldwide. Elevated LDL-C and reduced
HDL-C levels are well recognized CHD risk factors, with
recent evidence supporting the benefits of intensive LDL-
C reduction on CHD risk. Statins are a broadly used groupMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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of cholesterol-lowering agents that act by inhibiting the
enzyme 3-hydroxy 3-methylglutaryl CoA (HMG CoA)
reductase, which catalyzes the rate-limiting step in choles-
terol biosynthesis [299,300]; therefore, statins reduce the
concentration of downstream metabolic by-products
including mevalonate, which in turn leads to increased
LDL-receptor expression in hepatocytes and to increased
LDL-C uptake from the circulation. Statins also tend to
reduce apolipoprotein B and A-I production, as well as
additional antiinflammatory effects [301-303].
Lovastatin, simvastatin, pravastatin, fluvastatin, and ator-
vastatin are available in most parts of the world. Lovasta-
tin, simvastatin, and pravastatin are all fungal derivatives,
whereas fluvastatin and atorvastatin are synthetic. Lovas-
tatin and simvastatin are prodrugs and are converted into
their active forms (β-hydroxy acid) in the liver, whereas
the others are active in their parent forms. Concentration-
dependent HMG-CoA reductase inhibition in human
pharmacodynamic studies is based principally on plasma
LDL-C, which takes 4–6 weeks to show a reduction after
initiation of statin treatment. Fluvastatin, lovastatin, prav-
astatin, and simvastatin have similar pharmacodynamic
properties; all can reduce LDL-C by 20–35%. The liver is
the target organ for the statins, in that it is the major site
of cholesterol biosynthesis, lipoprotein production, and
LDL catabolism. Adverse HMG-reductase inhibitor effects
during long-term treatment may depend in part upon the
degree to which they act on extrahepatic tissues. There-
fore, pharmacokinetic factors such as hepatic extraction
and systemic exposure to (an) active compound(s) may
be clinically important when comparing statins. After
absorption, each undergoes extensive hepatic first-pass
metabolism. Up to five primary metabolites are formed,
some of which are active inhibitors. However, statins dif-
fer in certain important aspects concerning degree of
metabolism and number of active and inactive metabo-
lites. The rather extensive metabolism by different cyto-
chrome P450 isoforms also renders it difficult to
characterize these drugs with regard to tissue selectivity
unless all metabolites are well characterized. HMG-CoA
reductase-inhibitor availability is limited by extensive
first-pass metabolism. The CYP system is responsible for
the majority of the clearance of this class of drugs, with the
exception of pravastatin, in which renal clearance also
plays a major role in its elimination. Therefore, CYP iso-
zyme inhibitors may significantly raise HMG-CoA reduct-
ase-inhibitor serum levels. Lovastatin, simvastatin, and
atorvastatin are primarily oxidized by CYP3A4. Fluvasta-
tin is predominately (50–80%) inactivated by CYP2C9,
but CYP3A4 and -2C8 also contribute to its biotransfor-
mation. Pravastatin is not metabolized extensively by CYP
isozymes, but is selectively taken up by the sodium-inde-
pendent bile acid transporter. Caution must be exercised
with concurrent administration of drugs that interfere
with the CYP system in the presence of HMG-CoA reduct-
ase inhibitors.
Elimination half-lives range from 0.5–3.5 hours and
excretion is mainly via feces [304-306]. The common side
effects associated with these drugs are relatively mild and
often transient in nature. The only well documented, con-
sistent adverse effects associated with statins are muscle
toxicity, including myopathy and rhabdomyolysis, and
effects on liver enzymes; however, these effects are
uncommon and generally resolve rapidly when treatment
is stopped [307,308].
Results from large randomized controlled trials of statin
treatment have now provided confirmation that reducing
cholesterol and maintaining low cholesterol levels for at
least 5 years is not only safe but beneficial in the ability of
statins to reduce the risks of vascular death, non-fatal MI,
stroke, and the need for arterial revascularization proce-
dures [309]. In these trials, the extent of risk reduction was
judged as directly proportional to the degree to which
LDL-C was lowered, consistent with this being the main
mechanism [310,311]. Cholesterol-lowering is now rec-
ommended for a wide range of persons with cardiovascu-
lar risk, including those with average and below-average
lipid levels [312]. This change is leading to increased sta-
tin use and utilization of more intensive regimens.
Statins as anticancer agents
The mevalonate pathway is now considered an important
target for anticancer therapy, because its end-products are
critical for functioning in both normal and cancerous
cells. These products include geranylgeranyl pyrophos-
phate and farnesyl pyrophosphate [313]. Geranylgeranyl-
and farnesyl transferase employ geranylgeranyl pyrophos-
phate and farnesyl pyrophosphate, respectively, for post-
translational modifications of a wide variety of cellular
proteins. In this activation step, farnesyl or geranylgeranyl
moieties are coupled with the protein, resulting in a far-
nesylated or geranylgeranylated protein. This type of pro-
tein activation is referred to as (iso)prenylation. Several
proteins involved in signalling are dependent on prenyla-
tion for their activity, such as Ras, nuclear lamins, trans-
ducin c, rhodopsin kinase, Rho, and all of the remaining
heterotrimeric Gs [314,315]. These proteins regulate cell
proliferation, intracellular trafficking, and cell motility,
and this post-translational modification functions as a
membrane anchor critical for their activity [316,317].
There are several molecules being studied as anticancer
therapy that interfere with the mevalonate pathway. These
include farnesyl transferase inhibitors, geranylgeranyl
transferase inhibitors, dual inhibitors, bisphosphonates,
and statins, among others [313]. Blockade of this pathway
by statins results in decreased levels of mevalonate and itsMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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downstream products, influencing many critical cellular
functions.
Malignant cells appear highly dependent on sustained
availability of mevalonate pathway end-products [318].
Deregulated or elevated HMG-CoA reductase activity has
been shown in colorectal and gastric carcinomas, and
leukemia [319-321]. There are a number of pre-clinical
studies showing the antineoplastic effects of statins in in
vitro and in vivo systems against a number of cell lines
from solid and hematological malignancies. In general
and depending on cell type and experimental conditions,
statins exert growth arrest, apoptosis, antimetastatic and
antiangiogenic effects [322-325].
The antitumor mechanisms of statins are not yet well
defined. The most studied and perhaps the most impor-
tant effect lies at the isoprenylated protein level. Far-
nesylated Ras proteins are associated with mitogenic
signal transduction in response to growth factor stimula-
tion [326], whereas Rho subfamily proteins such as Rho,
Rac1, and Cdc42, regulate signal transduction from recep-
tors in the membrane in a variety of cellular events related
with cell morphology, cell adhesion, cell motility, cell
growth, and cancer cell metastasis [327,328]. RhoA and -
C are posttranslationally modified by geranylgeranyla-
tion, whereas RhoB can be farnesylated and geranylgeran-
ylated [329,330]. Thus, the majority of authors consider
inhibition of prenylation of these oncogenic proteins with
their consequent loss of function, due to the mechanism
that causes statin-induced effects on proliferation and
apoptosis. Statins also affect the Raf/MEK/ERK pathway in
a cell type-specific manner [331,332] and could also affect
PI3K-AKT pathways as farnesyltransferase inhibitors do
[333,334]. In addition, statins affect G1/S transition con-
trol by over-expression at either the mRNA or protein level
of Cdk inhibitors such as p16, -21, and -27 [335-337].
Other authors have suggested a p21- and p27-independ-
ent pathway for the effects of lovastatin. It has been
observed that proteasome inhibitors partially prevent lov-
astatin-induced E2F-1 degradation, suggesting that lovas-
tatin modulates E2F-1 proteasomal degradation, which
may be a critical regulatory mechanism of lovastatin-
induced effects [338], and that mevastatin inhibits cdk2
activity in PC3 cells through Thr-160 phosphorylation
inhibition of cdk2 [339].
The vast number of patients receiving statins for hyperc-
holesterolemia and pre-clinical evidence of their potential
antitumor effects has led to its evaluation in case-control
studies and meta-analyses for cancer incidence and their
effects on surrogate markers of cancer. As summarized by
Hindler et al. regarding statin use and cancer risk, three
studies (two with pravastatin and one with all statins)
have found a discrete increase in breast cancer and overall
cancer incidence. However, five studies found no changes
in cancer risk, whereas in five studies a large decrease in
melanoma, colorectal, breast, uterine, and prostate can-
cer, respectively, was found [332]. Further support for sta-
tin anticancer activity of statins derives from a small
prospective study to assess the effect of statin treatment on
serum prostatic specific antigen (PSA) in a cohort of air-
line pilots from 1992–2001. Despite that serum PSA was
significantly higher in the treatment group (p  = 0.05),
there was no significant difference between the groups on
subsequent follow-up, while a 41.6% decrease of PSA in
the treated group was observed [340]. It was also found
that statin use was associated with reduced Breslow thick-
ness or delayed metastasis of melanoma in a case-control
study including 1,318 cases and 6,786 controls from The
Netherlands [341].
Several phase I studies have been conducted. Tolerability
of pravastatin added to idarubicin and high-dose Ara-C
has been proven. In fact, the combination's maximum tol-
erated dose was not reached in the study, despite the use
of very high doses of pravastatin (up to 1,280 mg per day).
Response rates were encouraging, with a high number of
patients obtaining complete responses [342]. Likewise,
simvastatin administered for 7 days prior to chemother-
apy, VAD, or CHOP for myeloma and non-Hodgkin lym-
phoma, respectively, is safe up to a dose of 15 mg/kg
[343]. Lovastatin was administered in a dose-escalating
trial in subjects with advanced malignancies. Lovastatin
was administered at doses ranging from 10–415 mg/m2
every 6 hours for 96 hours in 4-week cycles. Dose-limiting
toxicity was not reached, demonstrating that high doses of
lovastatin in this schedule are well tolerated and that bio-
activity levels can be achieved [344]. Lovastatin as single
agent has also been studied in advanced head and neck
squamous cell carcinoma and cervical carcinoma. Maxi-
mum tolerated dosage (MTD) was determined as 7.5 mg/
kg/day × 21 days every 28 days, and relevant plasma lov-
astatin levels were obtained. Although no objective
responses were observed, median survival of patients in
the study was 7.5 months, and stable disease for > 3
months was observed in 23% of patients. Interestingly,
one patient achieved stable disease and clinical benefit for
14 months ON the study and a further 23 months OFF
treatment [345]. The strongest evidence from the antitu-
mor effects of statins was provided by Kawata et al., who
performed a small randomized trial in 91 patients with
unresectable hepatocellular carcinoma. Patients under-
went transcatheter arterial embolization followed by oral
5-FU at 200 mg/day for 2 months. Patients were then ran-
domly assigned to control (n = 42) and pravastatin (n =
41) groups at a daily dose of 40 mg. Median survival was
18 months in the pravastatin group vs. 9 months in con-
trols (p = 0.006). The Cox proportional hazards model
showed that pravastatin was a significant contributing fac-Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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tor to survival [346]. In general in all trials, statins were
well tolerated and the main toxicity observed was rhab-
domyolysis (muscle wasting), resolved with discontinued
use and ubiquinone supplementation. Further clinical
studies are strongly needed, particularly in combination
therapy with other biologicals and classical cytotoxics,
due to their synergy, as shown in several studies [347-
353].
Antimalarials
Chloroquine as antimalarial
Chloroquine is a 9-aminoquinoline specifically synthe-
sized for use as an antimalarial agent early in the 1930s.
This drug was widely used for malaria treatment and erad-
ication efforts, which faltered in the 1960s following the
development of drug-resistant parasites. Since that time,
no antimalarial regimen has contained malaria as success-
fully and cost effectively [354]. In addition to its use in the
antimalarial arsenal, chloroquine has been utilized for
treatment of autoimmune diseases such as rheumatoid
arthritis, due to its ability to slow the progress of the dis-
ease as a result of its immunomodulatory properties.
Rheumatologists have also used chloroquine for treating
systemic/discoid lupus erythematosus and other connec-
tive tissue disorders [355].
Chloroquine is commonly administered by oral route and
has a very high volume of distribution, because it diffuses
into the body's adipose tissue and is a lysosomotropic
agent, i.e., it accumulates preferentially in the lysosomes
of cells in the body. The pKa for the quinoline nitrogen of
chloroquine is 8.5, i.e., it is ~10% deprotonated at physi-
ological pH as calculated by the Henderson-Hasselbalch
equation. This decreases to ~0.2% at a lysosomal pH of
4.6. Because the deprotonated form is more membrane-
permeable than the protonated form, this results in a
quantitative trapping of the compound in lysosomes.
Chloroquine's lysosomotropic character is believed to
account for much of its anti-malarial activity. Chloro-
quine binds to heme to form what is known as the FP-
chloroquine complex; this complex is highly toxic to the
cell and disrupts the membrane's parasite function. The
action of the toxic FP-chloroquine and FP results in cell
lysis and ultimately, parasite cell autodigestion [356].
Chloroquine possesses a well known toxicity profile
established during > 50 years of use in humans, which
demonstrates the safety of its acute administration and
low incidence of adverse events during chronic adminis-
tration for periods of up to a few years. The most serious
toxic effect is a macular retinopathy, which depends on
the cumulative rather than the daily dose. The first report
of retinal toxicity attributed to this drug was published by
Cambiaggi [357], who described the classic retinal pig-
ment changes in a patient receiving chloroquine for sys-
temic lupus erythematosus treatment. One year later,
Hobbs established an unquestionable association
between long-term chloroquine use and the development
of retinal pathology [358]. This pathology associated with
chronic chloroquine use most likely results from chloro-
quine's affinity for melanin-containing structures, which
increases its accumulation in pigmented ocular structures
at concentrations much greater than in any other tissue in
the body, even long after its use is discontinued. Chloro-
quine also accumulates in lymphocytes and macrophages,
which results in antiinflammatory properties by reducing
secretion of proinflammatory cytokines, and in particular
of TNFα in monocytes/macrophages, as well as an impor-
tant decrease in TNFα-receptor surface expression in
human monocytic cell lines [359-361].
Chloroquine as anticancer drug
The mechanisms behind the effects of chloroquine on
cancer are currently being investigated. The best known
effects (investigated in clinical and pre-clinical studies)
include radiosensitizing effects through lysosome perme-
abilization and chemosensitizing effects by drug efflux
pump-transporter inhibition [362].
Chloroquine's lysosomotropic properties are the most
probable mechanisms for many of the drug's biological
effects, including radiosensitization. Because of its weak
base properties, chloroquine accumulates in several intra-
cellular organelles such as the endosome, Golgi vesicles,
and the lysosomes, leading to cell dysfunction of several
of these organelles [363]. In addition to its lysosomo-
tropic properties, chloroquine has the ability to modulate
cancer-cell autophagia, depending on the experimental
model. Autophagy is an ancient cell-survival pathway that
allows cells to recoup ATP and essential building blocks
for biosynthesis when they are nutrient-starved or
hypoxia-exposed, the hallmarks of the tumor microenvi-
ronment. This pathway involves the formation of double-
membraned vesicles, coined autophagosomes, which
envelop bulk cellular material and/or organelles and that
subsequently fuse with lysosomes that degrade their
cargo. Autophagy has been suggested to play important
roles in the chemoresistance of cancer to some therapeutic
agents, which typically induce an apoptotic response. To
the contrary, others have argued that autophagy induction
by anticancer agents increases their overall killing power,
enabling death by both classical apoptosis and autophagy
[364].
It has been suggested that chloroquine can affect p53-
dependent cell death by inhibiting autophagy [365-367].
While some reports have suggested that chloroquine stim-
ulates cell death by blocking the fusion of autophago-
somes with lysosomes [368-370], other studies haveMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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suggested that chloroquine inhibits a later stage of
autophagy by blocking degradation of cargo delivered to
the lysosome [365]. In a lymphomagenesis mouse model,
chloroquine showed to induce lysosomal stress and pro-
voked p53-dependent cell death, which that does not
require caspase-mediated apoptosis [371]. Existing pre-
clinical information of chloroquine's antitumor effects
and the broad experience in the use of this drug led Sotelo
and his group to launch a small clinical trial that exam-
ined the potential benefit of adding chloroquine to a
treatment regimen consisting of radiation plus carmustine
in patients with glioblastoma. Results of this randomized
phase II trial show that patients in the experimental arm
survived twice as long as patients treated with the conven-
tional regimen [372]. These provocative clinical results, as
well as the body of evidence showing the important role
of autophagy in cancer treatment, deserve the develop-
ment of antitumor therapies based on chloroquine-based
autophagic pathway modulation or on targeting other
steps in the pathway.
Antihormonal agents
Mifepristone as abortive
Mifepristone is a progesterone receptor antagonist and
abortive, but was originally investigated for its antigluco-
corticoid effects as a potential treatment for Cushing syn-
drome. In the presence of progesterone, mifepristone acts
as competitive receptor antagonist, but is a partial agonist
with weak activity when is present alone. Since 2000,
mifepristone (commercially available as Mifeprex) was
FDA-approved as abortive in combination with misopros-
tol.
Mifepristone acts at the receptor level, binding strongly to
progesterone and glucocorticoid receptors; its binding
affinity for these receptors is approximately five and three
times greater than progesterone and dexametasone,
respectively. Mifepristone, like progesterone, enters the
target cell and reaches its receptors; however, it operates
differently from progesterone, producing conformational
changes in the receptor. When progesterone occupies its
receptor, the receptor undergoes a conformational change
resulting in dissociation from heat shock proteins, trans-
location to the nucleus, and binding to progesterone
responsive elements (PREs) within target-gene promoter
regions. This binding leads to gene transcription and pro-
tein synthesis. Mifepristone antagonizes these effects by
occupying the receptor without stimulating gene tran-
scription [373,374].
The pharmacokinetics of mifepristone is characterized by
rapid absorption; time to peak serum levels is approxi-
mately 1–2 hours. Peak concentration rises according to
the mifepristone dose within the 2–25 mg-dosage range.
However, at a higher dose of 100–800 mg, Cmax values do
not differ significantly, this likely a result of saturation.
Bioavailability has been reported as 69% after oral intake
of 200 mg of mifepristone [375].
Mifepristone is protein-bound in ca 94–99%; binding is
principally to α1-acid glycoprotein (AAG). Distribution
volume in women is reduced as the result of saturable
high-affinity binding to AAG; therefore, serum AAG levels
appear to limit tissue availability and could exert an
impact on the pharmacokinetics of mifepristone in
humans [376]. Mifepristone metabolism is initiated by
rapid demethylation and hydroxylation in humans. Mife-
pristone half-life is 4 hours in rats, 15 hours in monkeys,
and 30 hours in humans. In vitro studies conducted with
human liver microsomes have shown that CYP450 3A4 is
largely responsible for oxidative metabolism. Therefore,
although specific drug or food interactions with mifepris-
tone have not been completely studied, it is possible that
ketoconazole, itraconazole, erythromycin, and grapefruit
juice may inhibit its metabolism and increase mifepris-
tone serum levels. In addition, rifampicin, dexametha-
sone, phenytoin, and phenobarbital may induce
mifepristone metabolism and lower mifepristone serum
levels. Demethylated and hydroxylated metabolites are
excreted into bile, and in humans, only a small fraction of
mifepristone can be detected in urine [377,378].
Mifepristone as anticancer agent
A number of studies have established that mifepristone
could effectively inhibit PR-positive breast cancer prolifer-
ation [379,380], ovarian cancer [381-383], endometrial
cancer [384], prostate cancer [385] and gastric cancer
[386]. Despite several reports demonstrating that mife-
pristone can inhibit human cell growth, only limited
information is available on the basic mechanism of this
effect. Some in-vitro and in-vivo mechanisms involved in
mifepristone antiproliferative effects in breast cancer
show that mifepristone induces growth arrest and cell
death, stimulating caspase-3, -8, and -9 activation in anti-
estrogen-resistant breast cancer cells [387]. It is known
that traditionally, caspase-8 activation is used as an activa-
tion indicator of the extrinsic apoptosis pathway, whereas
caspase-9 activation indicates involvement of the intrinsic
mitochondrial apoptosis pathway [388].
In the case of endometrial cell-proliferation regulation,
mifepristone is suggested as possessing an antioxidant
mechanism [389]. Apoptosis induction has been reported
by means of regulation of NF-kB [390], one of the early
response transcription factors that play an important role
in the regulation of genes involved in apoptosis. NF-kB
up-regulation in endothelial cells stimulates apoptosis by
75%. Simultaneously with a marked increase in NF-kB
activity, there is over-expression of the pro-apoptotic pro-
tein Bax, and down-regulation of the anti-apoptotic pro-Molecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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tein Bcl-2. It is also known that mifepristone can down-
modulate the over-expression of two proteins involved in
drug resistance, such as P-glycoprotein (P-gp) and Multi-
drug resistant protein (MRP) in lung cancer GLC4-Sb30
cells [391] and in human gastric adenocarcinoma SGC-
7901 cells [392]. Mifepristone also induced apoptosis in
human prostate cancer LNCaP cells by regulating Bcl-2
gene and TGFβ1 protein expression [385]. A cytostatic
effect of mifepristone has also been shown in ovarian can-
cer cells by blocking DNA synthesis and cell cycle arrest at
the G1-S transition via reduction of cdk2 activity, likely
due to increased cdk2 association with cdk inhibitors p21
and -27 and reduced nuclear cdk2/cyclin E complex avail-
ability [383].
Another interesting mechanism described for mifepris-
tone comprises its ability to modulate the activity of anti-
tumor compounds such as doxorubicin and vinka
alkaloids. There is evidence that some endogenous com-
pounds as steroid hormones interact with P-gp [393], and
corticosteroids and mineralocorticoids are also P-gp trans-
port substrates [394]. Moreover, some steroid antagonists,
such as tamoxifen and toremifen, interfere with P-gp func-
tion by virtue of their hydrophobicity and the presence of
phenyl rings [395], structural characteristics shared by
mifepristone. Thus, it has been reported that mifepristone
enhances doxorubicin cellular accumulation in resistant
human leukemia K562 cells and RHCL rat hepatoma cells
[396], suggesting an inhibitory effect on P-gp function, a
mechanism of action demonstrated for other chemosensi-
tizer agents including verapamil and cyclosporine.
Recently, it has been shown that mifepristone enhances
cisplatin chemosensitivity in resistant ovarian cancer cell
line [397], a finding consistent with the data of Liu et al.
[398], demonstrating, in a mouse model bearing
xenografted cisplatin-resistant ovarian carcinoma, signifi-
cantly greater inhibition rates of tumors in the combined
treatment in comparison with cisplatin treatment alone.
Data have recently been reported on mifepristone partici-
pation in modulation of the cisplatin effect in human cer-
vical cancer cell lines (negative estrogen [ER-] and
progesterone [PR-] receptors). Cisplatin's antiproliferative
effect was potentiated in combination with mifepristone
(10 μM). The results also showed that intracellular cispla-
tin levels increased approximately 2-fold due to mifepris-
tone pre-treatment. The mifepristone dose employed in
the previously mentioned work is within the plasma con-
centration range usually observed in humans after oral
administration of the drug [399].
The effect of mifepristone has also been widely studied in
meningioma, which is often progesterone – but not estro-
gen – receptor-positive. In this model, mifepristone elicits
potent growth-inhibitory effects in vitro and in human
xenografts. Interestingly, this agent is also active regardless
of the presence of the PR in meningioma cells, suggesting
off-target effects that contribute to their antitumor activity
[400,401].
Clinical studies of mifepristone have demonstrated its
anti-meningioma activity. In a study from The Nether-
lands, 10 patients with recurrent or primary inoperable
meningiomas, all of whom had shown recent neuroradi-
ological and/or ophthalmological evidence of tumor
growth, were treated with 200 mg mifepristone daily for
12 months. There were three patients with stable disease
and regression in three patients, as well as a decrease in
complaints of headache, and improved general well-being
was observed in five patients. Two patients died during
the treatment period from unrelated causes [402]. In a
larger study, 28 patients received daily oral mifepristone
at 200 mg/day for a total of 1,626 patient months-of-treat-
ment. Patients also received oral dexamethasone 1 mg/
day for the first 14 days of treatment. At a median therapy
duration of 35 months (range, 2–157 months), mifepris-
tone was well tolerated with mild fatigue (22 patients),
hot flashes (13 patients), and gynecomastia/breast tender-
ness (six patients), these three the most common side
effects. However, endometrial hyperplasia or polyps were
documented in three patients, and one patient developed
peritoneal adenocarcinoma after 9 years of therapy. In
another study, minor responses (improved automated
visual field examination or improved Computer tomogra-
phy or Magnetic resonance imaging scan were noted in
eight patients, seven of whom were males or pre-meno-
pausal females. Authors agree on the feasibility and toler-
ability of this treatment and on that even minor
regressions can result in significant clinical benefit [403].
A phase II study of mifepristone in cisplatin-resistant
ovarian cancer was reported in 44 patients who received
200 mg orally on a daily basis. Among response-evaluable
34 patients, overall response rate was 26.5% (nine
patients); of these, three (9%) had complete response,
and six (17.5%), partial. The response of one patient in
each group was measured by CA-125 levels, while the
remainder of patients had measurable disease. Responses
lasted 1–4 months in all but one patient and one patient,
who continued in response for > 3 years. The major toxic
effect was a rash [382]. Mifepristone appears to possess
activity against recurrent uterine leiomyosarcomas. A dra-
matic response lasting > 3 years was observed in one case
of three patients with recurrent low-grade progesterone
receptor-positive leiomyosarcoma [404].
Conclusions and perspectives
Drug-development strategies against cancer are changing.
After nearly 50 years of using cytotoxics, current antican-
cer drugs – approved and in development – were soughtMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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based on target-driven approaches, thus the name tar-
geted drugs. These drugs are regarded as specific, which
commonly means that they are aimed at hitting one or a
few key cellular targets. Agents that target single signaling
molecules often exhibit limited clinical activities, at least
in the major solid-tumor groups, with the exception of
certain well known examples represented by imatinib in
chronic granulocytic leukemia and gastrointestinal stro-
mal tumors, lending support to the gene addiction theory
[405]. This is not surprising, because agents that affect a
single target (single-hit agents) might not always affect
complex systems in the desired manner even if they
change the behavior of their immediate target completely.
For example, single targets might have back-up systems
that are sometimes sufficiently different in not responding
to the same drug, and many cellular networks are robust
and prevent major changes in their outputs despite dra-
matic changes in their constituents. These considerations
are independent of whether or not the pharmacological
agent inhibits or activates its target [406]. Paradoxically,
in drug development, it is common that poor specificity in
a drug is perceived as a negative characteristic. However,
this paradigm is changing, and the possibility of exploit-
ing promiscuity is considered in novel approaches for
treating complex disorders such as cancer, depression, and
cardiovascular disease [407-409]. Complex disorders ulti-
mately share the same underlying pathological processes
that play a particularly prominent role in their etiology.
These common mechanisms comprise, among others,
inflammation, angiogenesis, fibrosis, cellular prolifera-
tion, and defective apoptosis. Although inflammation is a
defense mechanism, an inappropriate inflammatory
response is the cause of many diseases, including cancer,
multiple sclerosis, inflammatory bowel disease, rheuma-
toid arthritis, endometriosis, arteriosclerosis, and psoria-
sis. Therefore, an understanding of the cellular effectors
and mediators that play key roles in the different inflam-
matory diseases can guide the ultimate positioning of
anti-inflammatory agents. Similarly, angiogenesis is a key
disease process in multiple indications, including tumor
development and metastasis, age-related macular disease,
arthritis, endometriosis, and psoriasis. Fibrosis is another
common mechanism that encompasses diseases with
prominent fibrotic etiology, such as lung fibrosis, liver cir-
rhosis, renal failure, and tissue scarring. Because fibrotic
processes are often downstream of inflammatory proc-
esses, inflammation and fibrosis may represent optimal
drug targets for the same disease at different clinical dis-
ease-progression stages. More than one common mecha-
nism may have an impact on a particular disease, as
observed in arthritis, endometriosis, and psoriasis, and
this may provide opportunities for combination therapies
with synergistic effects [410-412].
Simultaneous modulation of multiple targets is often
required to alter a clinical phenotype of robust systems
such as the molecular networks of living cells. Biological
redundancies and alternative pathways can often bypass
the inhibition of a single target or of multiple targets
along a single pathway, suggesting that in some cases,
broad-specificity compounds or multitarget drug thera-
pies may be more effective than individual high-affinity,
high-specificity therapies. Multiple but partial attacks
mimic a number of in vivo scenarios well and may be use-
ful in the efficient modification of other complex systems
[413]. Noteworthy examples of these concepts are the rel-
ative success of drugs inhibiting multiple kinases and/or
display off-target activities in the treatment of previously
difficult-to-treat diseases such as renal and liver carci-
noma, as well as cancer drugs that instead of hitting a sin-
gle gene product, hit processes such as proteosome, heat
shock protein 90 (Hsp90), and HDAC inhibitors [414].
With all this experimental and clinical evidence in the
cancer field, it comes as no surprise that a number of
widely used drugs for conditions other than cancer hit the
same primary and/or secondary targets of known antican-
cer drugs developed as such. Contrariwise, drugs devel-
oped as anticancer agents are used for benign conditions,
such as paclitaxel and bevacizumab for local catheter-
based, antiproliferative-drug delivery for prevention of
coronary restenosis and ocular neurovascular disease,
respectively [415,416]. Others, such as those whose off-
target effects on DNA methylation machinery led to think-
ing of them as anticancer agents remain to be studied. For
instance, the Na+ channels are the primary target of pro-
cainamide and procaine as antiarrhythmics and local
anesthetics, however, Na+ channels have recently found
to participate in cancer development [417]. Among all
these agents, perhaps the most remarkable is metformin,
which on targeting AMPK could be at least as – if not more
– effective than mTOR, Fatty acid synthase, and meval-
onate pathway inhibitors.
After all, cells work through signaling pathways [418].
Defining the role of pathways in complex diseases will
undoubtedly take many years. Perhaps, future textbooks
instead of being organized by organ and systems, pathol-
ogy, or physiology, will be categorized by the signaling
pathways involved. In this escenario, drugs would not be
denominated anticancer or antidiabetic or antihyperten-
sive; they would be named by the signaling pathway they
inhibit.
In the meanwhile, public and not-profit organizations
must be encouraged to rapidly translate the pre-clinical
data of known non-cancer drugs into phase II and III clin-
ical trials, as well as to conduct more research on the
potential cancer activities of this type of drugs. In the longMolecular Cancer 2008, 7:82 http://www.molecular-cancer.com/content/7/1/82
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run, these strategies may motivate changes that may aid in
cancer drug availability to a growing and underserved
population worldwide.
In 1881, the Mark Twain novel The Prince and the Pauper
was published. Set in 1547, the novel relates the story of
two young boys who are identical in appearance but who
live under opposite social circumstances, which render
them unable to function in the world that is as familiar to
one as to the other. In many ways, the book is a social sat-
ire, particularly compelling in its condemnation of the
inequality that existed among the classes in Tudor Eng-
land. The significance of the novel is quite contemporane-
ous with the current perception by researchers and
oncologists regarding cancer drugs. All of these – Oncolo-
gists, cancer researchers, and patients alike, and, why not,
biomedical journal editors with strong ties with the phar-
maceutical industry – must be aware that is not just
princely (read expensive) drugs that can help to treat can-
cer, but that pauper (read inexpensive) drugs are being
developed and bear the same potential for efficacy. If
these drugs eventually possess the latter, they should not
be regarded as pauper drugs solely because they are not
advertised by Big Pharma.
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